 
 
 
Protocol : J1I-MC- GZBD (c) 
 
 A Phase 2 Study of Once -Weekly LY3437943 Compared with Placebo and  
Dulaglutide in Participants with Type 2 Diabetes  
 
 
[STUDY_ID_REMOVED]   Approval Date: 2 9-Aug-2022 
CONFIDENTIAL  J1I-MC-GZBD (c) 
 1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the pro perty of 
Eli Lilly and  Company or its subsidiaries and should not be copi[INVESTIGATOR_597953] o f LY3437943 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
 
Protocol Title:  A Phase 2 Study of  Once -Weekly  LY3437943  Compared with Placebo and 
Dulaglutide in Pa rticipant s with Type 2 Diabetes  
Protocol Number: J1I-MC-GZBD  
Amendment Numb er: c 
Compound: LY3437943  
Study Phase:  Phase 2 
Short Title: Effect of LY3437943 Versus Placebo and Dulaglutide in Participants with Type 2 
Diabetes  
Sponsor Name: [CONTACT_11028]: Indianapolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s)  
IND: 145825  
Approval Date:  Protocol Amendment (c) Electronically  Signed and Approved  by [CONTACT_10937].   
Document ID:  VV-CLIN -072318  
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790762] Information  will be provided separately . 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 3 Protocol Amendment Summary of Changes Table  
 
DOCUMENT HISTORY  
Document  Date  
Amendment b  10-May-2021  
Amendment a  1-Mar-2021  
Original Protocol  19-Feb-2021  
Amendment  [c]  
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
The overall changes and rationale for the changes made in this amendment  are described in the 
following table.  
Section # and Name  [CONTACT_9353] 1.3 Schedule of 
Activities  
 Pharmacokinetic (PK) sample 
row: Updated sample ta ken at 
Visit 13 from Predose to 
Postdose  Dosing does not occur at Visit 
13 (Week 36); therefore, time 
point is now described as  
approximately [ADDRESS_790763] dose (Week 35).  
Pharmacokinetic Schedule of 
Events table  
Sample #11 row: Updated 
collection  time point from 
“Predose (up to 8 hours)” to 
“Postdose (approximately 1 
week)”  Dosing does not occur on 
Week  36. This sample collection 
time point is approximately [ADDRESS_790764] dose.   
Pharmacokinetic Schedule of 
Events table  
Sample #12 row:  Updated 
collection time  point from “[ADDRESS_790765] dose” to “[ADDRESS_790766] dose”  Since last dose is on Week 35, 
the Sample #[ADDRESS_790767] dose.  
Section 7.1 
Discontinuation of Study 
Intervention  Information about inadvertent 
enrollment has been removed.  Deleted as internal process will 
be followed for inadvertent 
enrollment.  
Section 7.2.1 
Discontinuation of 
Inadvertently Enrolled 
Participants  This section has been removed.  Deleted as internal pr ocess will 
be followed for inadvertent 
enrollment.  
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 4 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 7 
1.1. Synopsis  ................................ ................................ ................................ ............................ 7 
1.2. Schema  ................................ ................................ ................................ ............................ 10 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 11 
2. Introduction  ................................ ................................ ................................ ................... 18 
2.1. Study Rationale  ................................ ................................ ................................ ............... 18 
2.2. Background  ................................ ................................ ................................ ..................... 18 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 20 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ............. 20 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ ......... 20 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ ................................ ................... 20 
3. Objectives and Endpoints  ................................ ................................ ............................ 21 
4. Study Design  ................................ ................................ ................................ .................. 23 
4.1. Overall Design  ................................ ................................ ................................ ................ 23 
4.1.1.  Overview of Study Periods  ................................ ................................ ............................. 24 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 26 
4.3. Justification for Dose  ................................ ................................ ................................ ......27 
4.4. End of Study Definition  ................................ ................................ ................................ ..27 
5. Study Population  ................................ ................................ ................................ ........... 28 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 28 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 29 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .32 
5.3.1.  Meals and Dietary Restrictions  ................................ ................................ ....................... 32 
5.3.2.  Activity and Physical Exercise  ................................ ................................ ....................... 32 
5.4. Screen Failures  ................................ ................................ ................................ ................ 32 
6. Study Intervention  ................................ ................................ ................................ ........ 34 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 34 
6.1.1.  Medical Devices ................................ ................................ ................................ .............. 37 
6.2. Preparation/Handling/Storage/Accountability  ................................ ................................ 37 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 37 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 38 
6.5. Concomitant Therapy  ................................ ................................ ................................ .....39 
6.5.1.  Glucose -lowering Agents ................................ ................................ ................................ 40 
6.5.2.  Other Concomitant Medications  ................................ ................................ ..................... 41 
6.5.3.  Management of Participants with Gastrointestinal Symptoms  ................................ .......41 
6.6. Dose Modification  ................................ ................................ ................................ .......... 42 
6.6.1.  Temporary Interruption of Study Drug  ................................ ................................ ........... 42 
6.6.2.  Dose Reductions Indicated to Ensure Participant Safety  ................................ ................ 44 
6.7. Intervention after the End of the Study  ................................ ................................ ........... 45 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 46 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 46 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 5 7.2. Participant Discontinua tion/Withdrawal from the Study  ................................ ................ [ADDRESS_790768]  ................................ ................................ ................. 56 
8.4. Treatment of Overdose  ................................ ................................ ................................ ...62 
8.5. Pharmacokinetics  ................................ ................................ ................................ ............ 62 
8.5.1.  Bioanalysis  ................................ ................................ ................................ ...................... 62 
8.6. Pharmacodynamics  ................................ ................................ ................................ ......... 63 
8.7. Genetics  ................................ ................................ ................................ .......................... 63 
8.8. Biomarkers  ................................ ................................ ................................ ...................... 63 
8.9. Immunogenicity Assessments ................................ ................................ ......................... 64 
8.10.  Health Economics  ................................ ................................ ................................ ........... 64 
9. Statistical Considerations  ................................ ................................ ............................. 65 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....65 
9.2. Sample Size Determination  ................................ ................................ ............................ 65 
9.3. Populations for Analyses  ................................ ................................ ................................ 65 
9.4. Statistical Analyses  ................................ ................................ ................................ ......... 66 
9.4.1. General Considerations  ................................ ................................ ................................ ...66 
9.4.2.  Treatment Group Comparability  ................................ ................................ ..................... 67 
9.4.3.  Efficacy Analyses  ................................ ................................ ................................ ........... 67 
9.4.4.  Safety Analyses  ................................ ................................ ................................ ............... 68 
9.4.5.  Pharmacokinetic/Pharmacodynamic Analyses  ................................ ............................... 69 
9.4.6.  Evaluation of Immunogenicity  ................................ ................................ ....................... 69 
9.4.7.  Subgroup Analyses  ................................ ................................ ................................ ......... 69 
9.5. Interim Analyses  ................................ ................................ ................................ ............. 69 
9.6. Data Monitoring Committee (DMC)  ................................ ................................ .............. 70 
10. Supporting Documentation and Operational Consideration s ................................ ..71 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 71 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 71 
10.1.2.  Informed Consent Process  ................................ ................................ .............................. 72 
10.1.3.  Data Protection ................................ ................................ ................................ ................ 72 
10.1.4.  Committees Structure ................................ ................................ ................................ ......72 
10.1.5.  Dissemination of Clinical Stud y Data ................................ ................................ ............. 73 
10.1.6.  Data Quality Assurance  ................................ ................................ ................................ ..73 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 6 10.1.7.  Source Documents  ................................ ................................ ................................ .......... 74 
10.1.8.  Study and Site Start and Closure  ................................ ................................ .................... 75 
10.1.9.  Publication Policy  ................................ ................................ ................................ ........... 76 
10.1.10.  Investigator Information  ................................ ................................ ................................ .76 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 77 
10.3.  Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -Up, and Reporting  ................................ ........................ [ADDRESS_790769] Complaints  ................................ ................................ ................... 84 
10.3.4.  Recording and Follow -Up of AE and/or SAE and  Product 
Complaints  ................................ ................................ ................................ ...................... 85 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ .......... 87 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 87 
10.4.  Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy Information  ................................ ................................ ................................ ...89 
10.5.  Appendix 5: Liver Safety: Suggested Actions and Follow -Up 
Assessments  ................................ ................................ ................................ .................... 94 
10.6.  Appendix 6: Genetics ................................ ................................ ................................ ......96 
10.7.  Appendix 7: World Health Organization Classification of 
Diabetes and Diagnostic Criteria  ................................ ................................ .................... 97 
10.8.  Appendix 8: [LOCATION_001] Heart Association Functional 
Classification IV CHF  ................................ ................................ ................................ ....98 
10.9.  Appendix 9: Protocol GZBD Standardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, Vital 
Signs, ECG, SMBG and MNSI  ................................ ................................ ...................... 99 
10.10.  Appendix 10: Patient -Reported Outcomes  ................................ ................................ ...104 
10.11.  Appendix 11: Metabolic Mechanistic Biomarkers  ................................ ....................... 106 
10.12.  Appendix 12: Provisions for Changes in Study Conduct during 
Exceptional Circumstances  ................................ ................................ ........................... 108 
10.13.  Appendix 13: Abbreviations  ................................ ................................ ......................... 112 
10.14.  Appendix 14: Protocol Amendment History  ................................ ................................ 117 
11. References  ................................ ................................ ................................ .................... 119 
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 7 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:  A Phase 2 Study of Once -Week ly LY3437943  Compared with Placebo and 
Dulaglutide in Pa rticipant s with Type 2 Diabetes  
Short Title:  Effect of LY3437943 Versus Placebo and Dulaglutide in Participants with Type 2 
Diabetes  
Rationale:  
Epi[INVESTIGATOR_597954] 2 diabetes (T2D) and obesity are tightly associated 
(Verma and Hussain  2017 ; Marreno 2009). The ongoing  global obesity epi[INVESTIGATOR_597955] T2D and other  comorbidities , including hyperlipi[INVESTIGATOR_597956] - and macrovascular complications ( Garber 2012 ; Neeland et 
al. 2019 ; Dwivedi et al. 2020 ). In addition, obesity complicates treatment of T2D by [CONTACT_597976], preventing many patients from achieving the ir treatment goals  (Kahn et al. 
2006 ; Scheen and Van Gaal 2014 ; Barazzoni et al. 2018) . Glucose -lowering  therapeutic 
interventio ns that encompass weight loss may have a potential to slow the progression of T2D  
and reduce the risk of chronic complications (Lau and Teoh 2015 ; Aroda 2018 ; Pereira and 
Eriksson 2019 ; Chun and Butts 2020) . Treatments  that simultaneously target T2D and ob esity 
are considered an important unmet medical need . 
LY3437943 is a novel synthetic long-acting  peptide , which shows potent agonist action at 
glucose -dependent insulinotropic polypeptide (GIP), glucagon -like peptide -1 (GLP -1), and 
glucagon ( Gcg) receptors  (GIPR, GLP -1R, and GcgR) . It includes a linear  peptide component of 
[ADDRESS_790770] (GLP -1 RA) , as demonstrated by 
[CONTACT_597977]. In addition, LY3437943 demonstrated  greater  
weight loss in diet -induced obese (DIO) mice  compared with an existing GLP -[ADDRESS_790771] 
(GLP -1 RA) . The body weight reduction in DIO  mice  was primarily due to loss o f fat mass and 
was associated with lowered total plasma cholesterol and reduced liver fat content . 
Pharmacokinetic data from Phase 1 clinical studies support once -weekly administration of 
LY3437943 . In these trials, LY 3437943  was found to be safe and well tolerated, thereby 
[CONTACT_597978] a Phase 2 study . 
Study J1I-MC-GZB D (GZBD) is a Phase 2, multicenter, randomized, double -blind, parallel, 
placebo - and active comparator -controlled 36 -week study , with the primary outcome at 24 
weeks,  that will investigate glucose -lowering and body weight -lowering efficacy, as well as 
tolerability  and safety of LY3437943 in participants with T2D who failed to achieve adequate 
glycemic control on diet and exercise alone or on a stable dose of metformin ( 1000  mg/day for 
at least 3  months prior to Visit  1). The primary objective will be to  assess the  effect on 
hemoglobin A1c (HbA1c) after 24 weeks of treatment. Participants will be studied for a total of 
36 weeks of treatment to provide sufficient follow -up time to obtain additional weight loss 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 8 efficacy data over a longer time period. This study is de signed to support dose selection for 
Phase  3. 
Objectives and Endpoints  
Objectives  Estimands/E ndpoints  
Primary   
To demonstrate superiority  of QW LY3437943 (0.5, 
4.0, 8.0 , or 12.0  mg) in change from baseline for 
HbA1c relative to placebo , in participants with T2D 
inadequately controlled with diet and exercise with or 
without a stable dose of metformin  Change  in HbA1c (%) from baseline to [ADDRESS_790772] of QW LY3437943  versus 
placebo and versus  dulaglutide on: 
 Glucose control   
 
 Change in HbA1c from baseline to 24 
(dulaglutide comparison only) and 36 weeks  
 Percentage of participants reaching  HbA1c 
<7.0% at 24 and  36 weeks  
 
  Change in FBG  from baseline to 24 and 36 
weeks  (mg/dL, mmol/L)  
  
Body weight control  
 Change in body weight (kg) from baseline to 24 and 36 
weeks  
To assess s afety  and tolerability  of study interventions  
  Adverse events overall  
 Adverse events of special interest  
 Laboratory parameters  
 Electrocardiogram  
 Vital signs  
  Number of pa rticipant s testing positive  for 
anti-LY3437943 antibodies  
 
To assess PK of LY3437943 and po tential participant 
factors that may influence its PK  
  LY3437943  plasma concentration  
Abbreviations:  FBG = fasting blood glucose; HbA1c = hemoglobin A1c; PK = pharmacokinetics; QW = once -
weekly; T2D = type 2 diabetes.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 9 Overall Design  
Study GZBD is a Phase 2, multicenter, randomized, double -blind, parallel, placebo - and active 
comparator -controlled 36 -week study , with the primary outcome at 24 weeks,  to investigate the 
safety and efficacy of LY3437943 in participants with T2D who failed to achieve adequate 
glycemic control on diet and exercise alone or on a stable dose of metformin ( 1000  mg/day for 
at least 3 months prior to Visit  1). 
Disclosure Statement : This is a parallel group treatment study that is participant and 
investigator blinded.  
Number of Participant s: 
A total of approximately 300 participants will be randomized in a 2:2:2:1:1:1:1:2 ratio to either 
placebo, dulaglutide 1.5  mg, LY3437943  0.5 mg, LY3437943  4 mg (with starting dose at 2  mg; 
slow escalation ), LY3437943  4 mg (with starting dose at 4  mg; no escalation ), LY3437943 8 mg 
(with starting dose at 2  mg; slow escalation ), LY3437943 8 mg (with starting dose at 4  mg; rapid  
escalation ) or LY3437943  12 mg (starting dose at 2 mg; slow escalation) .  
Intervention Groups and Duration:  
There are 6 treatment arms, including placebo, 4 maintenance dose levels of LY 3437943 , and 
dulaglutide 1.5  mg. The maintenance doses in the 4 -, 8-, and 12 -mg dose range groups will be 
achieved using dose -escalation schemes, which will reduce the risk of tolerability issues and will 
occur in some LY3437943 treatment arms up to Week 12 by [CONTACT_597979] (or matched placebo).  Participants w ill be blinded as to whether she  or 
he is receiving either  
 LY3437943  and dulaglutide placebo ( single -dose pen; SDP ) or 
 Dulaglutide (SDP) and LY3437943 placebo or  
 LY3437943 placebo and dulaglutid e placebo.  
 
Data Monitoring Committee: No
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 10 1.2. Schema     
 
 
Abbreviations:  Dula = dulaglutide; LY = LY3437943; PBO = Placebo . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 11 1.3. Schedule of Activities (SoA)  
The Schedule of Activities described below should  be followed for all pa rticipant s enrolled in Study GZBD . However, for those 
participants  whose participation in this study is affected by [CONTACT_597980]  (such as pandemics or natural disasters), please 
refer to Section 10.12 , Appendix 12 for additional guidance.  
 
 Study Period 
I 
Screening/  
Lead -in Study Period II  
Treatment   Study Period I II 
Post -
Treatment 
Safety  Follow -
Up 
Visit  [ADDRESS_790773] 
end of TXP  
Allowable Interval Tolerance 
(days)  ±5 ±5 - ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 
Fasting Visit  X  X X X X X X X X X X X X X 
Administrative  
Informed consent  X               
Inclusion and exclusion criteria 
review  X X X             
Demographics  X               
Preexisting conditions and 
medical history, including 
relevant surgical history  X               
Medical  history  includes  assessment  of relevant  preexisting  conditions  (for example, history  of 
gallbladder  disease,  cardiovascular  disease,  medullary  thyroid carcinoma , and pancreatitis ). 
Concomitant medications  X X X X X X X X X X X X X X X 
Adverse events and product 
complaints  X X X X X X X X X X X X X X X 
Physical Evaluation  
Height  X               
Weight  X  X X X X X X X X X X X X X 
Body weight must be measured in the fasting state. If th e participant is not fasting, the participant 
should return at a later date  within the visit window to have the fasting body weight measured.  
Waist circumference  X  X     X X  X  X X  
Vital signs  (3 sitting BP and PR 
measurements)  X  X X X X X X X  X  X X X 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 12  Study Period 
I 
Screening/  
Lead -in Study Period II  
Treatment   Study Period I II 
Post -
Treatment 
Safety  Follow -
Up 
Visit  [ADDRESS_790774] 
end of TXP  
Allowable Interval Tolerance 
(days)  ±5 ±5 - ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 
Fasting Visit  X  X X X X X X X X X X X X X 
 Vital sign measurements should be taken before obtaining an ECG tracing and before collection of 
blood samples for laboratory testing (See Section 10.9 ). 
Supi[INVESTIGATOR_597957] 
(orthostatic vital signs)    X      X  X  X   
Referral to Section 10.9  for description of the orthostatic vital sign measurements.  
Physical examination  
 X          X  X X X 
 Visit 1 should be a complete physical while other  visits should be “targeted” exams based on the 
physician ’s judgment . 
12-Lead electrocardiogram  X  X   X X X X  X  X X X 
Singlet -electrocardiograms should be obtained  prior to collection of blood samples for laboratory 
testing,  including PK samples  (see Section 10.9  Appendix 9).  
Participant Education and Supplies  
Blood glucose (BG) meter 
instructions   X X             
Dispense BG meter/supplies (if 
needed)   X    X X X X X X X    
Diabetes education   X              
Diabetes education to be performed by [CONTACT_134097], SMBG, self -injection, and diabetes 
management. All trainin gs should be repeated as needed to ensure part icipant compliance.  
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c) 
 13  Study Period 
I 
Screening/  
Lead -in Study Period II  
Treatment   Study Period I II 
Post -
Treatment 
Safety  Follow -
Up 
Visit  [ADDRESS_790775] 
end of TXP  
Allowable Interval Tolerance 
(days)  ±5 ±5 - ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 
Fasting Visit  X  X X X X X X X X X X X X X 
Blood Glucose Monitoring  
Remind participants about 7 -
point SMBG   X      X  X  X    
7-point SMBG    X      X  X  X   
Review SMBG and hypoglycemic 
events  in the diary  for diabetes 
management    X X X X X X X X X X X X X 
Participant Diary (paper)  
Participant diary dispensed   X X          X   
Diary compliance check    X X X X X X X X X X X X  
Diary return    X X X X X X X X X X X X X 
Patient -Reported Outcomes (paper)  
SF-36v2 acute form    X        X  X X  
Eating Inventory    X        X  X X  
Appetite Visual Analog Scale    X   X X X X  X  X X  
  If a translation is not available in the native language of a participant at baseline, the PRO 
questionnaire(s) will not be administered for that participant for the duration of the trial (Appendix 
10.10 ). 
Laboratory Tests and Sample Collections  
Hematology  X     X  X   X  X X X 
Hemoglobin A1c (HbA1c)  X  X   X X X X  X  X X X 
Clinical chemistry  X  X     X X  X  X X X 
Glucose  X  X  X X X X X  X  X X X 
Lipid panel  X  X   X X X X  X  X X  
Urinalysis  X     X  X   X  X X  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 14  Study Period 
I 
Screening/  
Lead -in Study Period II  
Treatment   Study Period I II 
Post -
Treatment 
Safety  Follow -
Up 
Visit  [ADDRESS_790776] 
end of TXP  
Allowable Interval Tolerance 
(days)  ±5 ±5 - ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 
Fasting Visit  X  X X X X X X X X X X X X X 
Serum pregnancy  X               
For women of childbearing potential only  
Urine pregnancy (local)  
   X             
A urine pregnancy test must be performed at Visit [ADDRESS_790777] injection of 
study intervention(s) for women of childbearing potential only. Additional pregnancy tests (beyond 
those required per the SoA) should be p erformed at any time during the trial if a menstrual period is 
missed, there is clinical suspi[INVESTIGATOR_51940], or as required by [CONTACT_51967].  If the urine pregnancy 
test is inconclusive at Visit 3, the recommendation would be to collect an additional ser um pregnancy test .  
Follicle stimulating hormone 
(FSH)  X               
Only for postmenopausal women at least [ADDRESS_790778] of biomarkers  
eGFR (CKD -EPI) X  X     X X  X  X X  
Urinary albumin/creatinine ratio 
(UACR)  X  X      X  X  X X  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 15  Study Period 
I 
Screening/  
Lead -in Study Period II  
Treatment   Study Period I II 
Post -
Treatment 
Safety  Follow -
Up 
Visit  [ADDRESS_790779] 
end of TXP  
Allowable Interval Tolerance 
(days)  ±5 ±5 - ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 
Fasting Visit  X  X X X X X X X X X X X X X 
Pharmacokinetic 
(PK) sample  
 Predose    X X  X  X   X X    
Postdose      X  X  X X   X X X 
 Efforts should be taken to align clinical visit scheduling with PK sampl ing windows  specified in the 
Pharmacokinetic Schedule of Events  table below ; otherwise, participants  may need to return to the 
clinical site for additional PK -specific visits to provide PK samples.   
Immunogenicity (ADA) samples    X   X  X   X  X X X 
Stored Samples  
Genetic sample 
(pharmacogenetic stored sample)    X             
Exploratory stored samples 
(nonpharmacogenetic st ored 
samples)    X  X X X X X  X  X X  
Randomization and Dosing  
IWRS  X X X X X X X X X X X X X X X 
Randomization    X             
Observe participant administer 
study intervention    X             
Participants should administer their first dose of study drug  at the end of Visit 3, after ot her study 
proce dures and randomization have been completed. Further observation and information on self -injection can 
be reviewed as necessary throughout the study . 
Dispense study intervention and 
injection supplies    X   X X X X X X X    
Review injection technique     X X X X X        
Drug accountability     X X X X X X X X X X X  
Participant returns unused study 
intervention and injection 
supplies      X X X X X X X X X X  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 16  Study Period 
I 
Screening/  
Lead -in Study Period II  
Treatment   Study Period I II 
Post -
Treatment 
Safety  Follow -
Up 
Visit  [ADDRESS_790780] 
end of TXP  
Allowable Interval Tolerance 
(days)  ±5 ±5 - ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 
Fasting Visit  X  X X X X X X X X X X X X X 
Assess drug compliance     X X X X X X X X X X X  
Abbreviations:  ADA = anti -drug antibody;  BG = blood glucose; BP = blood pressure; CKD -EPI = chronic kidney disease -epi[INVESTIGATOR_623];  
ECG  = electrocardiogram; ED = early discontinuation; eGFR =estimated glomerular filtration rate ; HbA1c  = hemoglo bin A1c; IWRS  = Interactive Web 
Response Systems;  PK = pharmacokinetics ; PR = pulse rate; SF-36v2 acute form  = Short Form -36 Version 2 Health Survey acute form; SMBG = 
self-monitoring of blood glucose ; TXP = treatment period; wks = weeks.  
Note s: 
 Visit [ADDRESS_790781] be completed before processing the randomization in the IWRS.  
 The visit date is determined in relation to the date of Visit 3 (randomization).  
 Participants who are unable or unwilling to continue the study treatment for any reason will per form an E D visit. If the participant is discontinuing 
during an unscheduled visit or a scheduled visit, that visit should be performed as an E D visit.  
 Visit 801 (safety follow -up visit) should be performed [ADDRESS_790782] treatment p eriod  visit.  
 For fasting office visits, remind participants to report to the site before taking study drug(s) i n a fasting condition, after a period of at least  8 hours 
without eating, drinking (except water), or any si gnificant physical activity. Since some screening procedures need to be completed in the fasting state, 
Visit 1 may be conducted over more than 1 day to ensure necessary conditions are met. The participant should not take any ant ihyperglycemic 
medications prior to the fasting visit.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 17 Pharmacokinetic Schedu le of Events  
 
Sample #  Week Relative to Randomization  Collection Timepoint Relative to LY3437943 Weekly Dose  
1 0 Predose (up to -8 hours)* 
2 1 Predose (up to -8 hours) 
3 2 1 to 24 hours postdose  
4 4 Predose (up to -8 hours)* 
5 8 24 to 72 hours postdose  
6 12 Predose (up to -8 hours)* 
7 16 72 to 168 hours postdose   
8 20 Any time during this week  
9 24 Predose (up to -8 hours)* 
10 30 Predose (up to -8 hours) 
11 36 Postdose ( approximately 1 week )* 
[ADDRESS_790783] dose * 
13 Early discontinuation  Any time * 
 * Immunogenicity (ADA) samples collected with PK at these visits.
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 [ADDRESS_790784] shown that T2D and obesity are  tightly associated ( Marrero  2009; 
Verma and Hussain  2017). The ongoing  global obesity epi[INVESTIGATOR_597958] T2D 
and other comorbidities , including hyperlipi[INVESTIGATOR_597959] - and macr ovascular complications  (Garber 2012; Neeland et al. 2019 ; 
Dwivedi et al. 2020) . In addition, o besity complicates treatment of T2D by [CONTACT_597981], preventing many patients from achieving the ir treatment goals  (Kahn et al. 2006 ; 
Scheen and Van Gaal 2014 ; Barazzoni et al. 2018) . Glucose -lowering  therapeutic intervention s 
that encompass weight loss may have a potential to slow the progression of T2D  and reduce the 
risk of chronic complications  (Lau and Teoh 2015 ; Aroda 2018 ; Pereira and Erikss on 2019 ; 
Chun and Butts 2020) . Treatments  that simultaneously target T2D and obesity are considered an 
important unmet medical need.   
Glucose -dependent insulinotropic polypeptide (GIP) , glucagon -like peptide -1, and glucagon 
(Gcg)  have a role in the regulation of carbohydrate, protein and lipid metabolism , and energy 
balance. While some of their actions are similar, each hormone also has unique metabolic 
regulatory actions, providing an opportunity to combine their respective actions in a single 
molec ule to develop a pharmacological agent with improved efficacy and safety profile for the 
treatment of a range of metabolic conditions compared with existing therapi[INVESTIGATOR_014].  
LY3437943 is a novel synthetic single peptide  with triple receptor activity in GIP, GLP -1, and 
Gcg receptors ( GIPR, GLP -1R, and GcgR , respectively ). 
In Phase [ADDRESS_790785] inadequate 
glycemic control with diet and exercise with or without  a stable dose of metformin . The primary  
objective at Week 24 will be to assess  superiority of QW LY3437943 ( 0.5, 4, 8 , or 12  mg) in 
change from baseline for HbA1c (%) relative to placebo . Participants will be studied for a total 
of 36 weeks of treatment to provide sufficient follow -up time to obtain additional weight loss 
information. This trial is designed to support dose selection for Phase  3 development . 
2.2. Background  
Type 2 diabetes is characterized by [CONTACT_597982] -cell failure  (Zheng et al. 
2018) . Type 2 diabetes  is commonly associated with comorbidities such as obesity, hypertension, 
and dyslipi[INVESTIGATOR_597960].  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 [ADDRESS_790786] action at GIP , GLP -1, and Gcg 
receptors (GIPR , GLP -1R, and GcgR , respectively ).  
Nonclinical  data with efficacy and toxicology  
In nonclinical pharmacology models, LY3437943 demonstrated equal or greater effect on  
glucose -dependent insulin secretion  compared with an existing GLP -[ADDRESS_790787] in lean rats and with greater  weight loss in DIO mice . The 
body weight reduction in DIO mice  was primarily due to loss of fat mass . 
 
 
 
 
 
 
 
 
 
 
 
Summary of clinical studies  
Study J1I -MC-GZBA (GZBA)  was a  first-in-human , single -ascending dose (SAD) study 
investigating  the safety, tolerability, and PK/PD of LY3437943 ( dose ranging from 0.1 to 6 mg) 
administered as a SC injection in [ADDRESS_790788] common treatment emergent adverse events ( TEAEs ) were gastrointestinal ( GI) 
events, including vomiting, abdominal distention, and nausea, which  were dose dependent, 
mostly mild in severity,  occurred within 4 days of dosing, and resolved within a week of onset . 
Dose -dependent increases in heart rate (HR) and decreases in systolic blood pressure were 
observed, which returned to near baseline  by [CONTACT_2006] 29 . 
Across dose levels, the m aximum  observed  drug concentration (C max) occur red between ~1 and 
3 days postdose, while t he mean terminal half -life was  ~5 to 7 days, thus supporting a QW 
dosing regimen .  
Study J1I -MC-GZB B (GZB B) is an ongoing  Phase 1 , randomized, investigator - and 
participant -blind 12-week study t hat assess es the safety, tolerability, and PK/PD effects of 
multiple doses of LY3437943 when administered QW in participants  with T2D . Trulicity® 
(dulaglutide)  1.5 mg is  used as a n active  comparator . Participant s in Cohorts 1 to 3  are receiv ing 
fixed doses of LY3437943  (0.5, 1.5 , or 3 mg QW ) or placebo for  12 weeks . Participants in 
Cohort s 4 and 5 are receiving escalated doses starting from 3 mg to 12 mg, respectively, over  the 
12-week  treatment period . 
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c) 
 20 Based on preliminary data  from this study , 72 participants in all treatment arms received study 
treatment, and 43 completed the study  to date.  Gastrointestinal AEs (nausea, abdominal 
distention , and diarrhea ) and decreased appetite were the most frequently reported events, mostly 
mild in severity and dose dependent . A dose -dependent increase in HR was noted.  The HR 
effects were consistent with those of the GLP -1 or GIP/GLP -1RA class, as was s een in Phase 1 
clinical development. There were no reports of severe hypoglycemia or AEs related to the site 
injection . Overall, data from early phase clinical trials support further development of 
LY3437943 in Phase 2 studies . 
2.3. Benefit/Risk Assessment  
This section summarizes the key observations from the completed or ongoing Phase 1 trials with 
LY3437943. More detailed information about the known and expected benefits and risks and 
reasonably expected adverse events of LY3437943  may be found in t he Investigator’s Brochure  
(IB). Information on AEs expected to be related to the investigational product may be found in 
Section  6.2 (Development al Core Safety Information)  of the IB. Information on SAEs that are 
expected in the study population independent of drug exposure will be assessed by [CONTACT_365191], periodically during the course of the study, and may be found in Section  7 (Reference 
Safety Information for Assessment of Expectedness of Serious Adverse Reactions ) of the IB . 
More detailed information about the known and expected benefits and risks of dulaglutide may 
be found in the USPI [INVESTIGATOR_2808] (Trulicity  USPI,  2020 ; Trulicity  SmPC,  2020). 
2.3.1.  Risk Assessment  
Most common AEs seen in clinical trials of LY3437943 have been those related to the GI organ 
system. The GI AEs, as well as those related to pancreatic safety, hypoglycemia, vital signs, 
allergic and hypersensitivity reactions, and thyroid C -cell effects are safety topi[INVESTIGATOR_597961], therefore, be assessed in this study, too. Most 
of these AEs have not been observed with LY3437943 in the completed or ongoing phase trials. 
Please refer to the IB Section [ADDRESS_790789] of the GIP, GLP -1, and glucagon receptors that is currently in early 
clinical development. Full assessment of its potential benefits has not been completed. The 
purpose of this Phase 2 trial is to provide initial efficacy assessm ent in participants with T2D, in 
addition to safety and PK/PD assessments.  
2.3.3.  Overall Benefit: Risk Conclusion  
The data from Phase 1 studies indicate that the safety profile of LY3437943  is consistent with 
the safety profile of other GLP -1 and GIP/GLP -1 RAs . No additional risks are anticipated.  
Considering  the measures to minimize risk to participants included in the study protocol , 
potential risks identified in association with LY3437943  are considered acceptable in this study . 
No benefits can be assumed sinc e LY3437943 is in the early phase of clinical development. All 
participants taking part in this study will receive diet and physical activity counseling according 
to site programs.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 21 3. Objectives  and Endpoints  
Objectives  Estimands/En dpoints  
Primary   
To demonstrate superiority of QW LY3437943 (0.5, 
4.0, 8.0, or 12.0 mg)  in chang e from baseline for 
HbA1c relative to placebo , in participants with T2D 
inadequately controlled with diet and exercise with 
or without a stable dose of metformin  Change in HbA1c  (%) from baseline to [ADDRESS_790790] of QW LY3437943  versus 
placebo and versus dulaglutide  on: 
 Glucose control   
 
 
 Change in HbA1c (%) from baseline to 24 
(for dulaglutide comparison only)  and 36 
weeks  
 Percentage of participants reaching HbA1c of  
<7.0%  at 24 and/or 36 weeks  
 
  Change in FBG  from baseline to 24 and 36 
weeks  (mg/dL, mmol/L)  
 
 Body weight control  
  Change in body weight (kg) from baseline to 
24 and 36 weeks  
 
To assess safety  and tolerability  of study intervention    Adverse events overall  
 Adverse events of special interest  
 Laboratory parameters  
 Electrocardiogram  
 Vital signs  
  Number of pa rticipant s testing positive for 
anti-LY3437943 antibodies  
To assess the PK of LY3437943 and potential 
participant factors that may influence its PK   LY3437943  plasma concentrations  
Tertiary/Exploratory  
To assess the relationship between LY3437943 dose 
and/or exposure and key efficacy and safety 
measures  and potential participant factors that may 
influence these relationships   Dose –response and concentration –response 
analyses  for key efficacy and safety 
parameters  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 22 Objectives  Estimands/En dpoints  
To compare the effect of QW LY3437943  versus  
placebo and versus  dulaglutide  on: 
 Glucose control   
 
 
 Change in SMBG profile from baseline to 24 
and 36 weeks  
  Percentage of participants reaching HbA1c of 
<5.7%, <6.5% , and <7.0%  at 24 and/or 36 
weeks  
Dose –response including placebo   
 Body weight control   Percentage of participants with 5 %, 10%, 
15%, or greater body weight loss from 
baseline to 24 and 36 weeks  
 Dose –response including placebo  
 
 Appetite VAS   Change from baseline to 4, 8, 12, 16, 24, and 
36 weeks  
 
 Lipi[INVESTIGATOR_805]   Change from baseline to 16, 24, and 36 weeks 
for total cholesterol, triglycerides, HDL  
cholesterol, LDL cholesterol, and VLDL 
cholesterol  
 
 Biomarkers   Change from baseline to Week 16, 24, and 36 
weeks for mechanistic biomarkers (see 
detailed list of parameters in Section 10.11 ) 
 
 Patient -reported outcomes   Mean change from baseline to Weeks 16, 24, 
and 36 for:  
SF-36v2 acute form domain score s 
Eating Inventory domain scores  
Abbreviations:  FBG = fasting blood glucose; HbA1c = hemoglobin A1c; HDL = high -density lipoprotein; LDL = 
low-density lipoprotein; PK = pharmacokinetics; QW = once -weekly; SF-36v2 = Short Form -36 version 2 Health 
Survey ; SMBG = self -monitoring of blood glucose; T2D = type 2 diabetes; VAS = Visual Analog Scale; VLDL = 
very low -density lipoprotein.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 23 4. Study Design  
4.1. Overall Design  
Study GZBD is a Phase 2, multicenter, randomized, double -blind ed, parallel, placebo - and active 
comparator -controlled 36 -week study , with the primary outcome at 24 weeks,  to investigate the 
safety and efficacy of LY3437943 in participants with T2D who failed to achieve adequate 
glycemic control on diet and exercise alone or on a stable dose of metformin ( 1000  mg/day for 
at least 3  months prior to Visit  1) (see Section 1.2). 
Four maintenance doses of LY3437943 will be evaluated in the trial, 0.5, 4, 8 , and 12  mg. Dose  
escalation to reduce the ri sk of tolerability issues will occur in certain treatment groups up to 
Week 12 by [CONTACT_597983] (or placebo) . For maintenance 
doses equal to or greater than 4 mg, the initial dose will be 2 or 4  mg followed by [CONTACT_597984] 4.1.1 . Study participants will be 
randomized in a 2:2:2:1:1:1:1:2 ratio to either placebo, dulaglutide 1.5  mg, LY3437943  0.5 mg, 
LY3437943  4 mg (with starting dose at 2  mg; slow escalation ), LY3437943  4 mg (with starting 
dose at 4  mg; no escalation ), LY3437943 8 mg (with starting dose at 2  mg; slow escalation ), 
LY3437943 8 mg (with star ting dose at 4  mg; rapid  escalation ), or LY3437943  12 mg (with 
starting dose at 2  mg; slow escalation ). 
All participants will undergo a 3-week screening period , a 36-week treatment period , followed 
by a 4 -week safety follow -up period.   
During the 36 -week t reatment period, each participant will receive one injection of LY3437943 
or placebo (PBO) administered with a syringe and one injection of dulaglutide or PBO 
administered with a n SDP (see Section 6 for more details ). The table below specifies the number 
of injections per treatment arm.  
 
Number of Injections Per Treatment Arm  
Randomization  LY3437943  PBO 
LY3437943  Dulaglutide 
1.5 mg SDP  PBO 
Dulaglutide 
SDP  Total  
LY 0.5  mg 1 0 0 1 2 
LY 4  mg 1 0 0 1 2 
LY 8  mg 1 0 0 1 2 
LY 12  mg 1 0 0 1 2 
Dulaglutide 1.5  mg 0 1 1 0 2 
PBO  0 1 0 1 2 
Abbreviations: LY = LY3437943 ; PBO = placebo; SDP = single -dose pen . 
 
During the trial, an unblinded internal assessment committee (AC) will review safety , 
tolerability , and efficacy data in study participants according to a prespecified schedule in order 
to assure the safety of randomized participants (see Section 9.5). 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 [ADDRESS_790791] sign 
the informed consent form (ICF) before the study procedures are performed, as outlined in the 
SoA, Section 1.3. Screening procedures will be performed according to the SoA (Section 1.3).  
Visit [ADDRESS_790792] key study 
information, as appropriate. Participants will start recording their self-monitoring of blood 
glucos e (SMBG) values and hypoglycemic events immediately after Visit [ADDRESS_790793] study visit. See Section 10.9 for details about glucose self -
monitoring.  
Diabetes education will be performed by [CONTACT_597985],  self-monitored BG, self -
injection , and diabetes management  according to American Diabetes Association Standards of 
Medical Care in Diabetes (ADA 2020) or local standards . Participants will be trained on how to 
utilize BG meters and how to collect SMBG, in cluding 7 -point measurements as appropriate. 
Blood glucose meters or supplies will be provided to measure SMBG values (see Section 10.9).  
Visit [ADDRESS_790794] dose of study drug s will be recorded on the 
electronic case report form  (eCRF) . Beginning at randomization, all participants will receive 
study drug s according to the randomized treatment arm for the duration of the 36-week treatment 
period  as per the SoA (Section 1.3).  
  
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c) 
 25 Treatment Period  
During the Treatment Period, study drugs and injection supplies will be returned per the SoA 
(Section  1.3) and according to local requirements. New supplies will be dispensed as needed. 
Participants should be instructed to contact [CONTACT_597986].  
Participants should also be advised about the appropriate course of action if study drugs are not 
taken at the required time (late/missing doses) (see Section 6.6.1 ). Study participants will be 
permitted to use concomitant medications that they require duri ng the study, except certain 
excluded medications (see Section 6.5) that may interfere with the assessment of efficacy and 
safety characteristics of the study treatments.  
Dose -Escalation  Period (Visits 4 -8) 
For maintenance doses of LY3437943 equal to or greater than 4 mg, the initial dose will be 2 or 
4 mg followed by [CONTACT_597987] . Study site 
personnel will continue to train participants o n how to use the syringe and vial at each dose 
titration visit during dose escalation and as needed during the trial.  The dose will be increased at 
4-week increments until the maintenance dose is achieved (see Section 6.1 for dosing details), as 
follows:  
 Maintenance dose of 0.5  mg: no dose escalation  
 Maintenance dose of 4  mg will be randomized 1:1 into 2 subsets:  
o 2 mg  4 mg (slow escalation)  
o 4 mg (no dose escalation)  
 Maintenance dose of 8  mg will be randomized 1:1 into 2 subsets:  
o 2 mg  4 mg  8 mg (slow escalation)  
o 4 mg  8 mg (rapid escalation)  
 Maintenance dose of 12  mg:  
o 2 mg  4 mg  8 mg  12 mg (slow escalation).  
The maintenance doses of LY3437943 or dulaglutide 1.5  mg will be continued for the  remainder 
of the study. In participants who experience intolerable GI symptoms or may need dose 
adjustment for other reasons, the dose can be changed as described in Section  6.5.1 .  
Maintenance  Period (Visits 9 -13) 
During the maintenance period, visits will occur every 4 weeks until 24 weeks and then every 6 
weeks from Weeks 24 to 36. Visit procedures should be conducted according to the SoA 
(Section  1.3). At Visits 10 and 12, when collected, patient -reported outcomes questionnaires 
should be administered as early as possible in the visit and in the preferred administration order 
(Section 1.3). 
Early Discontinuation Visit  
Participants unable or unwilling to continue the study for any reason will perform an early 
discontinuation (ED) of treatment visit (Section 7.1). If the participant is discontinuing during an 
unscheduled visit or a scheduled visit, that visit should be performed as an ED visit. Procedures 
should be completed according to the SoA (Section  1.3). Participants who discontinue from the 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 26 study early and perform ED visit should also perform Visit 801 (see below) approximately [ADDRESS_790795] treatment period 
visit. All participants are required to complete a safety follow -up visit (Visit  801), according to 
the SoA (Section  1.3). Participants discontinuing the study early and performing an ED visit will 
also be asked to perform the safety follow -up visit.  
Participants are also required to return any remaining study diaries to the study site at the end of 
this period.  
4.2. Scientific Rationale for Study Design  
Study G ZBD  is a Phase  2 study designed to examine the glucose and body weight -lowering 
efficacy and safety of LY 3437943  QW (dose ranging from 0.5 to 12  mg) compared with placebo 
and dulaglutide 1.[ADDRESS_790796] 
inadequate glycemic control with diet and exercise alone or in combination with  a stable dose of 
metformin.  
LY3437943 was well tolerated up to a 3 -mg dose in the single ascending dose study (Study 
GZBA) and up to a 12 -mg dose with gradual dose escalation in the multiple ascending dose 
study (Study GZBB). Therefore, the highest dose in this study will be 12 mg. In addition, 2 dose 
escalation schemes are desig ned to provide information on optimal dose escalation schemes for 
Phase 3 clinical development.  
The placebo comparison will provide efficacy and safety data to characterize the effects 
attributable to LY3437943. Inclusion of an active comparator (dulaglut ide 1.5 mg) will allow for 
a direct comparison of QW LY3 [ADDRESS_790797] long -term outcome of diabetes.  In addition, the protocol 
includes other parameters relev ant to the assessment of the effects on treatment interventions of 
glucose control, body weight control, safety, and mechanism of action .  
The primary objective will be tested at 24 weeks since this period is considered as adequate for 
evaluation of glucos e-lowering efficacy in a Phase 2 trial. The full planned duration of 36 weeks  
will allow for a n initial  comparison of the body weight effects of the study  drugs . The putative 
mechanism of action of LY 3437943  suggests that treatment with LY 3437943  may resul t in 
continued weight loss over this treatment  period. The data from this trial will form the primary 
basis to assess dose –response/exposure –response of LY3 [ADDRESS_790798] benefit –risk 
characterizations in treatment of  T2D. 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 27 The current study will enroll pa rticipants  with inadequate glycemic control based on HbA1c  
values ranging from 7 .0% to 10.5%,  inclusive. The study population, as defined by [CONTACT_64466], is expected to include participants  with modestly advanced T2D and partially 
preserved pancreatic  cell function, the key prerequisit e for glucose -lowering efficacy of 
incretins.  Stable metformin treatment for at least [ADDRESS_790799] of changes in concomitant medications, 
participant s will be permitted to use concomitant medications that do not interfere with the 
assessment of efficacy or safety characteristics of the study treatments.  
4.3. Justification for Dose  
LY3437943  maintenance  doses of 0.5, 4, 8, and 12 mg, administered  subcutaneously QW, were 
selected based on  
 Safety and tolerability of LY3 437943  in healthy subjects  and T2D patients in the Phase 1 
studies GZBA (0.1 to 6  mg) and GZBB  (0.5 to 12  mg), respectively . 
 PK/PD modeling based on preliminary data from Study GZBB.  
 Acceptable margin of safety for the [ADDRESS_790800] level in rats and monkeys in the  6-month toxicology studies.  
 A maintenance  dose of 0.5 mg is being investigated in this study to enable full 
characterization of the exposure –response  relationships. This dose is predicted  to achieve 
LY34379 43 concentration levels that will demonstrate greater HbA1c lowering compared 
with placebo , but less than that of 1.5  mg dulaglutide .  
 Maintenance d oses of 4, 8, and [ADDRESS_790801] on tolerability  and safety findings . 
 The selected dose levels and dose range will  support a robust dose –exposure –response  
analysis of multiple safety and efficacy measures to support selection of dose(s) o f 
LY3437943  with optimal benefit/risk ratio for further clinical development . 
4.4. End of Study Definition  
A participant is considered to have completed the study if he  or she has completed all required 
phases of the study including the last visit  or the last scheduled pr ocedure shown in the  SoA 
(Section 1.3). 
The end of the study is defined as the date of the last visit of the last participant in the study or 
last scheduled procedure shown in the S oA for the last participant in the trial globally.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 28 5. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclus ion Criteria  
Participants are eligible to be included in the study only if all of the following criteria are met : 
Age 
1. Participant must be  [ADDRESS_790802] been diagnosed with T2D based on the World Health Organization (WHO) 
classification (see Section 10.7) or other locally applicable diagnostic standards  
3. Have an HbA1c value at screening of 7.0% and 10.5% and treated with diet and 
exercise alone or with a stable dose of metformin (either immed iate release or extended 
release, 1000  mg/day and not more than the locally approved dose) for at least 3  months 
prior to screening/Visit  [ADDRESS_790803] had a stable body weight for the 3 months  prior to randomization (5 kg body weight 
gain and/or loss) 
5. Have not  modified diet or adopted any nutritional lifestyle modification within [ADDRESS_790804] a body mass index (BMI) of 25 -50 kg/m2 at Visit 1  
 
Sex 
7. Contraceptive use by [CONTACT_225368].  
Men, women of childbearing potential, and women not of childbearing potential (for 
definitions, see Section 10.4) can participate in this study considering the following:  
 males agree to refrain from sperm donation and to use contraceptive methods 
as described in Section 10.[ADDRESS_790805] injection.  
 women of childbearing potential agree to use contraceptive methods as 
described in S ection 10.[ADDRESS_790806] injection. Female 
participants should not be breastfeeding . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 29 Note:  Hormone replacement therapy in post -menopausal women and contraceptives 
containing an estrogen and a progestin (oral or transdermal system) in pre -
menopausal women are allowed but women must be on stable ther apy for 3 months 
prior to screening/Visit 1.  
8. In the investigator’s opi[INVESTIGATOR_1649], are well motivated, capable, and willing to  
 perform finger -stick BG monitoring, including scheduled BG profiles with up 
to 7 measurements in 1 day  
 learn how to self -inject study dr ugs ( LY3437943 /placebo  and 
dulaglutide/placebo), as required for this protocol (visually impaired persons 
who are not able to perform the injections must have the assistance of a 
sighted individual trained to inject the study drugs; persons with physical 
limitations who are not able to perform the injections must have the assistance 
of an individual trained to inject the study drugs)  
 inject  study intervention  QW, and  
 maintain study diaries, as required for this protocol.  
Informed  Consent  
9. Capable of giving signed informed consent as described in  Section  10.1.[ADDRESS_790807] ies: 
Medical Conditions  
10. Have type 1 diabetes mellitus (T1DM)  
11. Have history of ketoacidosis or hyperosmolar state/coma  
12. Have a history of prolif erative diabetic retinopathy, diabetic maculopathy, or severe 
nonproliferative diabetic retinopathy that requires immediate treatment intervention  
13. Have  a history of severe hypoglycemia and/or hypoglycemia unawareness within the [ADDRESS_790808] a known clinically significant gastric emptying abnormality ( for example, severe 
diabetic gastroparesis or gastric outlet obstruction), have u ndergone gastric by[CONTACT_6476] 
(bariatric) surgery or restrictive bariatric surgery (for example, Lap -Band®), or chronically 
take medications that directly affect GI motility  
16. Have ob esity induced by [CONTACT_597988] (such as Cushing’s syndrome or 
Prader -Willi syndrome)  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 [ADDRESS_790809] uncontrolled hypertension (systolic blood pressure above or equal to 160  mmHg 
and/or diastolic blood pressure above or equal to 100  mmHg) . For participants with 
uncontrolled hypertension at the screening visit, antihypertensive medication may be 
started. Blood pressure must meet the protocol criterion for hypertension control by [CONTACT_4838] 
[ADDRESS_790810] an elevated  resting pulse rate (>100  bpm) at baseline  
19. Have any of the following cardiovascular conditions within 3 months prior to Screening : 
 acute myocardial infarction   
 cerebrovascular accident (stroke ) 
 unstable angina,  or  
 hospi[INVESTIGATOR_597962] (CHF).  
20. Have an ECG considered by [CONTACT_597989]  
 
21. Have a history  of [LOCATION_001] Heart Association Functional Classification III or IV CHF 
(see Section 10.8) 
22. Have acute or chronic hepatitis, signs, and symptoms of any liver disease other 
than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) 
level >3.0 times the upper limit of normal (ULN) for the refer ence range, as 
determined by [CONTACT_291591]. Participants with NAFLD are 
eligible to participate in this trial if their ALT level is ≤3.[ADDRESS_790811] an estimated glomerular filtration rate <45 mL/min/1 .73 m2 (or lower than 
the country -specific threshold for discontinuing metformin therapy per local label) , 
calculated by [INVESTIGATOR_82351] -Epi[INVESTIGATOR_597963] 1 )  
24. Have  family or personal history of medullary thyroid carcinoma (MTC) or 
multiple endocrine neoplasia syndrome type 2 (MEN2)   
25. Have evidence of a significant, uncontrolled endocrine abnormality (for example, 
hypothyroidism, thyrotoxicosis, or adrenal crises), in the opi[INVESTIGATOR_1070]  
26. Have a s erum calcitonin level of ≥ 20 ng/L, if eGFR ≥  60 mL/min/1.73 m2 or ≥35 
ng/L if eGFR < 60 mL/min/1.[ADDRESS_790812](s), to selective GLP -1 
RAs or GIP/GLP -1 or GLP -1/Gcg dual receptor agonists  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 [ADDRESS_790813] evidence of a significant, active autoimmune abnormality (for example, 
lupus or rheumatoid arthritis) that, in the opi[INVESTIGATOR_871], is likely to 
require concurrent treatment with systemic glucocorticoids in th e next [ADDRESS_790814] had a transplanted organ (only corneal transplants [keratoplasty] allowed) or 
awaiting an organ transplant  
30. Have a history of an active or untreated malignancy or are in remission from a 
clinically significant malignancy (other than ba sal or squamous cell skin cancer, in 
situ carcinomas of the cervix, or in situ prostate cancer) for less than [ADDRESS_790815] had a blood donation of [ADDRESS_790816] known 
hemoglobinopathy  (for example , hemolytic anemia or sickle cell anemia ), or have a 
hemoglobin value <11  g/dL (males) or <10  g/dL (females), or any other condition known 
to interfere with HbA1c measurements  
32. Have a history of an y other condition (such as known drug, alcohol abuse, or 
psychiatric disorder) that, in the opi[INVESTIGATOR_871], may preclude the 
participant from following and completing the protocol  
Prior/Concomitant Therapy  
33. Any glucose -lowering medications othe r than metformin within [ADDRESS_790817] been treated or plan to be treated with prescription or over -the-counter 
(OTC ) medications that promote weight loss within 3  months prior to screening  
For example   
 Saxenda ® [liraglutide 3.0  mg]  
 Xenical ® [orlistat]  
 Meridia ® [sibutramine]  
 Acutrim ® [phenylpropanolamine]  
 Sanorex ® [mazindol]  
 Adipex® [phentermine]  
 BELVIQ ® [lorcaserin]  
 Qsymia ™ [phentermine/topi[INVESTIGATOR_81063]]  
 Contrave ® [naltrexone/bupropi[INVESTIGATOR_2394]] , or  
 other similar body weight loss medication , including OTC medications, for 
example, allī ®. 
 
35. Have received chronic (>2  weeks or 14 days) systemic glucocorticoid therapy (excluding 
topi[INVESTIGATOR_2855], intraocular, intranasal, intra -articular, or inhaled preparations) within 1 month 
prior to scre ening  
Prior/Concurrent Clinical Study Experience  
36. Are currently e nrolled in a clinical study involving an IP or any other type of medical 
research judged not to be scientifically or medically compatible with this study  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 [ADDRESS_790818] 30 days of screening, in a clinical study 
involving an IP; at least 5 half -lives or 30 days (whichever is longer) should have 
passed  
38. Have previously completed or withdrawn from this study or any other study 
inves tigating  LY3437943  
Other Exclusions  
39. Are investigator site personnel directly affiliated with this study and/or their 
immediate families. Immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally adopted  
40. Are Eli Lilly and Com pany employees or are employees of any third  party 
involved in study who require exclusion of their employees  
41. Are, in the opi[INVESTIGATOR_26335], unsuitable for inclusion in the 
study  
5.3. Lifestyle Considerations  
Per the SoA (Section 1.3), qualified medical staff will provide diabetes management counseling, 
which will include instructions on diet and exercise and education about  the signs, symptoms, 
and treatment of hypoglycemia  and hyperglycemia , should it occur.  Throughout the study , 
participants may undergo medical assessment s and review of compliance with re quirements 
before continuing in the study . 
Study participants should be instructed not to donate blood or blood products during the study . 
5.3.1.  Meals and Dietary Restrictions  
Participants  should continue their usual meal plan  (with consistent meal size and time of day) 
throughout the course of the study , as agreed with the investigator or his  or her designee . Per 
Inclusion Criterion 5 (Section 5.1), participants  should not initiate a  structured  diet and/or 
exercise progr am for weight reduction during the study other than the lifestyle and dietary 
measures for diabetes treatment.   
For certain assessments, the participants will be required to come to the site in a fasting state, 
after an overnight fast (except for water) of  at least 8 hours when clinical laboratory assessments 
and/or weight measures are performed as specified in the S oA (Section  1.3).  
5.3.2.  Activity  and Physical Exercise  
Participants will be advised to maintain their regular levels of physical activity/exercise during 
the study; strenuous exercise within 24 hours prior to all  visits should be avoided.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently  enrolled in the study . A minimal set of screen failure information is required to 
ensure trans parent reporting of screen failure participants to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details,  eligibility criteria, 
and any serious adverse event (SAE) .  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
 33 Individuals who do not meet the criteria for participation in this study (screen failures) may be 
rescreened  only once at the discretion of the investigator. Before rescreening is performed, the 
participant must sign a new ICF and receive a new identification number.  If, in the opi[INVESTIGATOR_144086], an ineligible lab test result is the result of an error or exceptional  circumstance, then 
that parameter can  be retested once without the participant having to be rescreened  as outlined in 
Section 10.12 . 
 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBD (c)  
 34 6. Study Intervention  
Study intervention is defined as any investiga tional intervention(s), marketed product(s), placebo, or medical device(s) intended to be 
administered to/used by a study participant according to the study protocol.  
6.1. Study Intervention(s) Administered  
The following study interventions will be administered : 
 LY3437943 vial containing 12 mg/2 mL of solution or  
 Placebo to match LY3437943 vial containing 2 mL of solution  
and 
 Dulaglutide 1.5 mg/0.5 mL single -dose pen or  
 Placebo to match Dulaglutide in a 0.5 mL single -dose pen  
Treatment  Arm  
Escalation Period Dose  Maintenance Period Dose  
LY weekly 
dose/  
Administered 
as 12-Week Escalation Period  24-Week Dosing  
Week 0 to Week 3  Week 4 to Week 7  Week 8 to Week 11  Week 12 through Week 35  
0.5 mg LY3437943a/1.5 
mg dulaglutide (dula) 
PBO  LY weekly dose 
(no escalation)  0.5 mg LY QW  0.5 mg LY QW  0.5 mg LY QW  0.5 mg LY QW  
Administered as  
 1 dose 0.5 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 0.5 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 0.5 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 0.5 mg LY  
1 dose 1.5 mg dula PBO  
4 mg LY3437943/1.5 mg 
dulaglutide (dula) PBO  
 LY weekly dose  
(slow escalation)  2 mg LY QW  4 mg LY QW  4 mg LY QW  4 mg LY QW  
Administered as  1 dose 2 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 4 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 4 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 4 mg LY  
1 dose 1.5 mg dula PBO  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBD (c)  
 35 LY weekly dose  
(no escalation)  4 mg LY QW  4 mg LY QW  4 mg LY QW  4 mg LY QW  
Administered as  1 dose 4 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 4 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 4 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose  4 mg LY  
1 dose 1.5 mg dula PBO  
8 mg LY3437943/1.5 mg 
dulaglutide (dula) PBO  
 LY weekly dose  
(slow escalation)  2 mg LY QW  4 mg LY QW  8 mg LY QW  8 mg LY QW  
Administered as  1 dose 2 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 4 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 8 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 8 mg LY  
1 dose 1.5 mg dula PBO  
LY weekly dose  
(rapid 
escalation)  4 mg LY QW  8 mg LY QW  8 mg LY QW  8 mg LY QW  
Administered as  1 dose 4 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 8 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 8 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 8 mg LY  
1 dose 1.5 mg dula PBO  
12 mg LY3437943/1.5 
mg dulaglutide (dula) 
PBO  LY weekly dose  
(slow escalation)  2 mg LY QW  4 mg LY QW  8 mg LY QW  12 mg LY QW  
Administered as  1 dose 2 mg LY  
1 dose  1.5 mg dula 
PBO  1 dose 4 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 8 mg LY  
1 dose 1.5 mg dula 
PBO  1 dose 12 mg LY  
1 dose 1.5 mg dula PBO  
1.5 mg 
Dulaglutideb/LY3437943 
PBO  Dula weekly 
dose 1.5 mg dula QW  1.5 mg dula QW  1.5 mg dula QW  1.5 mg dula QW  
Administered as  1 dose 1.5 mg dula  
1 dose LY PBOc 1 dose 1.5 mg dula  
1 dose LY PBOc 1 dose 1.5 mg dula  
1 dose LY PBOc 1 dose 1.5 mg dula  
1 dose LY PBOc 
PBO weekly  
dose PBO  PBO  PBO  PBO  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL  J1I-MC-GZBD (c)  
 36 Placebo (LY3437943 
PBO/1.5 mg dulaglutide 
PBO)  Administered as  1 dose LY PBOc 
1 dose 1.5 mg dula 
PBO  1 dose LY PBOc 
1 dose 1.5 mg dula 
PBO  1 dose LY PBOc 
1 dose 1.5 mg dula 
PBO  1 dose LY PBOc  
1 dose 1 .5 mg dula PBO  
Abbreviations: dula  = dulaglutide; LY =  LY3437943; PBO  = placebo; QW = once -weekly . 
a LY3437943  QW will be administered by [CONTACT_597990] a 12 mg/2 mL vial.  
b Dulaglutide  QW will be administered using a single -dose pen .  
c LY3437943  PBO will be randomly assigned to follow the injection dose  schedule for one active LY arm.
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790819] injections of study drugs should occur at Visit 3 immediately after randomization. 
Subsequently, administrations should be scheduled on the same day  of the week  and 
approximately the same time  of the day. If a dose of study drug (s) is missed on the regularly 
scheduled day, the participant  should administer  it as soon as possible , unless less than  [ADDRESS_790820] be detected, 
documented, and reported by [CONTACT_23528] (see Section 10.3.3 ). 
6.2. Preparation/Handling/Storage/Accountability  
 The investigator or designee must confirm appropriate storage conditions have been 
maintained during transit for all study intervention received and any discrepancies 
are reported and resolved before use of the study intervention.  
 Only participants enrolled in the study may receive study intervention. Only study 
personnel may supply, prepare, or administer study intervention. All study 
intervention must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with 
access limited to the investigator and authorized study personnel.  
 The investigator -authorized  study personnel are responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is , receipt, 
reconciliation, and final disposition records).  
 Further guidance and information for the final disposition of unused study 
interventions are provided in the  study training materials.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
At Visit 3,  participant s who meet all criteria for en rollment will be randomized to 1 of the 6 
study treatment groups  and 2 different starting d ose subgroups within the 4 and 8 mg 
LY3437943 treatment groups. Assignment to treatment groups  and starting dose subgroups  will 
be determined by a computer -generated random sequence using an interactive web -response 
system (IWRS) with the following stratif ication variables: baseline HbA1c (<8.5%, 8.5%) and 
BMI (<30, 30). Study participants will be randomized in a 2:2:2:1:1:1:1:2 ratio to either 
placebo, dulaglutide 1.5  mg, LY3437943  0.5 mg, LY3437943  4 mg (with starting dose at 2  mg), 
LY3437943  4 mg (with  starting dose at 4  mg), LY3437943 8 mg (with starting dose at 2  mg), 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 38 LY3437943 8 mg (with starting dose at 4  mg), or LY3437943  12 mg (with starting dose at 2 
mg). 
This is a double -blind study.  All participants will administer 2 weekly injections (syringe 
containing LY3437943 or PBO, single -use pen containing dulaglutide 1.5 mg or PBO) matching 
their treatment allocation, as described in Section 6.1. Therefore, each participant will be 
administering one of the following study drug combinations in a blinded fashion:  
 LY3437943  and dulaglutide placebo (SDP)  
 Dulaglutide (SDP) and LY3437943 placebo , and   
 LY3437943 placebo and dulaglutide placebo.  
Where required, dose escalation of LY3437943 (or matched placebo) will be done by [CONTACT_597991].  To preserve the blinding of the study, a minimum 
number of Lilly personnel will see the randomization table and treatment assignme nts before the 
study is complete.  
Emergency unblinding may be performed through the IWRS.  This option may be used ONLY if 
the participant’s well -being requires knowledge of  the participant’s treatment assignment. All 
unblinding events are recorded and repo rted by [CONTACT_8784] . 
If an investigator , site personnel performing assessments, or participant is unblinded, the 
participant must be discontinued from the study. In cases where there are ethical reasons to have 
the participant remain in the study, the investi gator must obtain specific approval from a sponsor 
clinical research physician (CRP) for the  participant to continue in the study.  
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a participant’s treatm ent assignment is warranted for medical management of the event. The 
participant ’s safety must always be the first consideration in making such a determination. If a 
participant’s treatment assignment is unblinded, Lilly must be notified immediately. If th e 
investigator decides that unblinding is warranted,  it is the responsibility of the investigator to 
promptly document the decision and rationale and notify Lilly as soon as possible.   
6.4. Study Intervention Compliance  
Partic ipant compliance with study interve ntion s will be assessed at each visit. Compliance will 
be assessed by [CONTACT_597992]/or empty 
cartons returned. Study intervention  compliance will be determined by [CONTACT_716]:  
 Study intervention admini stration data will be recorded in the diary by [CONTACT_597993].  
 The participant s will be instructed to return any unused study drug s and/or empty 
cartons at the next visit to the study site for the purpose of performing study drug 
accountability.  
Treatment compliance will be assessed every [ADDRESS_790821] 75% of the required  SC 
doses of study drug s.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 39 In additi on to the assessment of a participan t’s compliance with administration  of study drug s, 
other aspects of compliance with the study treatments will be assessed at each visit based on the 
participant ’s adherence to the visit schedule, completion of study diaries, and any other 
parameter s the investigator considers necessary.  
Participant s cons idered to be poorly compliant with their medication and/or the study procedures 
will receive additional training and instruction, as required, and will be reminded of the 
importance of complying with the protocol.  
6.5. Concomitant Therapy  
Participants will be permitted to use concomitant medications that they require during the study,  
except certain medications that may interfere with the assessment of efficacy and safety  of the 
study treatments . The table below p rovides a summary of criteria for use of concomi tant 
medications that may interfere with planned assessments during the study.  
 
 Criteria for Use of Concomitant Medications that May Interfere with Efficacy and Safety 
Assessments in Study GZBD  
Abbreviations:  DPP-4 = dipeptidyl peptidase -4; GLP -1 RA = glucagon -like peptide -[ADDRESS_790822]; N = no; N/A 
= not applicable; SGLT2 = sodium -glucose co -transporter 2; Y = yes. 
a Acute therapy = treatment for up to 14 days.  
b Rescue  therapy is glucose -lowering intervention added to manage severe persistent hyperglycemia, as defined in 
Section [IP_ADDRESS]  
c See Section 5.2  
d From 1 month  prior to Visit 1 or between Visits 1 and 3; does not  apply to topi[INVESTIGATOR_2855], intraocular, intranasal, 
intra-articular, or inhaled preparations .  
e Switch ing metformin manufacturers is allowed as long as the dosage is the same.  
f For rescue therapy, metformin dose can be increased if the dose is below maximum approved dose per country -
specific label.  
 Drug Class  Use during 
Screening/Lead -In Conditions for Use after Randomization  
Acute 
Therapya Rescue 
Therapyb  During Safety 
Follow -Up Period  
Drugs with approved weight loss 
indicationc Excluded  N N/A Y 
Systemic glucocorticoid therapyd Excluded except for 
acute therapya Y N/A Y 
Antihyperglycemia medications  
Other GLP -1 RAs  Excluded  N N N 
DPP-4 inhibitors  Excluded  N N N 
SGLT2 inhibitors  Excluded  N Y Y 
Insulins and insulin mixtures  Excluded except for 
acute therapya  Y Y Y 
Meglitinides  Excluded  N Y Y 
Alpha -glucosidase inhibitors  Excluded  N Y Y 
Sulphonylureas  Excluded  N Y Y 
Thiazolidinediones  Excluded  N Y Y 
Metformine Optional  N/A Yf Y 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790823] consult with the investigator or a  
designated site staff member upon being prescribed any new medications during the study. This  
may not be possible  when initiated for treatment of medical emergencies, in which case, the  
participan t will inform the investigator or a designated site staff member as soon as possible. 
Any additional medication initiated during the course of the study (including OTC drugs , such as  
paracetamol or aspi[INVESTIGATOR_248]) must be documented, and the name [CONTACT_81155](s) of  
administration must be recorded on the “Concomitant Medications” section of the eCRF.  
6.5.1.  Glucose -lowering Agents  
The only concomitant antihyperglycemic medicatio n permitted at baseline  is metformin. 
Metformin  dose must be stable  for at least 3  months prior to screening.   
 Participant s who enter the study on diet and exercise alone will not be allowed to initiate 
metformin therapy after study entry , unless if rescue  therapy is required (for more details 
see below) . 
 Participant s who are being treated with metformin upon entering this study should remain 
on the same metformin dose throughout the course of the study . A change in dose is 
allowed only after randomization when needed  to protect the participant’s safety  (see 
below for further details) . If needed between screening and randomization, that 
participant will be discontinued from the trial.  
 If a pa rticipan t switches from the immediate -release formulation of metfo rmin to the 
sustained -release formulation, the change will be on a milligram per milligram basis.  
 
After randomization, discontinuation of metformin or change in dosage and formulation is  
permitted in the following situations:  
 
In the event of a hypoglyce mic epi[INVESTIGATOR_1865](s) (clinical symptoms of hypoglycemia and/or  
BG-confirmed symptomatic BG hypoglycemia: glucose concentration <3.0 mmol/L [ <54 
mg/dL]: participants  may reduce/discontinue the dose of metformin.  
In certain situations that require short -term disco ntinuation in line with the product(s)  
labeling for each respective country (for example, severe dehydration,  elective surgery, or 
need for radiologic examination involving IV iodinated contrast dye).  Once the situation 
that led to temporary discontinuatio n of the drug is resolved, treatment  should be 
restarted at investigator ’s discretion.  
If a participant develops contraindications to metformin such that the use of the drug is  
contraindicated according to the country -specific label.  
If a participant meets  the criteria for severe, persistent hyperglycemia or  discontinues 
study drug s, then metformin may be added (for participants managed by [CONTACT_17977]/exercise 
alone) or the metformin dose may be increased according to country -specific  label as 
long as that is not the sole intervention  (see Section [IP_ADDRESS] ). 
 
A participant  will be considered noncompliant with the protocol (protocol deviation) if he or she  
chang es the dose or discontinues metformin for reasons other than those described here.  Dose 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 41 reduction  or discontinuation of metformin during the trial should be properly documented and  
recorded on the appropriate eCRF.  
 
Glucose -lowering medications other than study drugs and metformin are not allowed at any  time 
during the study except for those participants  who require permanent discontinuation  of study 
drugs, but remain in the study , rescue therapy after randomization due to severe,  persistent 
hyperglycemia  (criteria provided in Section [IP_ADDRESS] ), or during the safety follow -up period  as 
indicated in the table above (Section 6.5). Short -term insulin use for up to 14 days is allowed for 
certain clinical situations (for example, elective  surgery, during hospi[INVESTIGATOR_059], and 
hyperosmolar states) and must be differentiated from insulin use  as rescue therapy when reported 
in the eCRF.  
All nonstudy medications will be recorded in the eCRF at all visits.  
Nonstudy medications taken by [CONTACT_597994] l not be reported to Lilly unless an SAE or AE occurs that the investigator believes  
may have been caused by a study procedure.  
6.5.2.  Other Concomitant Medicatio ns 
Treatment with medications  that are excluded per entry criteria (Section  5.2, Exclusion Criteria ) 
is not permitted  during the trial . 
Doses of prescription medications for treatment of concurrent medical conditions should remain 
constant during the study unless an adjustment is medically indicated. When needed, t he sponsor 
should be contact[CONTACT_597995]. If an additional 
concomitant medication is already started, the sponsor should be informed as soon as possible.  
Doses of antihypertensive and lipid -lowering therapi[INVESTIGATOR_597964]. For example, doses of 
antihypertensive  medication may be reduced if the  participant’s  blood pressure declines 
significantly during the study resulting in symptoms of lightheadedness or may be increased 
during a hypertensiv e crisis . 
Nonsteroidal anti -inflammatory medications (including ibuprofen  and aspi[INVESTIGATOR_248]), acetaminophen, 
cough suppressants, antihistamines, vitamin/mineral supplements, antibiotics, and topi[INVESTIGATOR_597965] -needed basis without notifying t he sponsor and are not restricted 
by [CONTACT_597996] . Any additional medication used during the 
course of the study (including those not requiring sponsor notifications) must be documented on 
the appropriate eCRF . Specifically  excluded concomitant medications are listed in Section 5.2. 
6.5.3.  Management of Participants with Gastrointestinal Symptoms  
Consistent with other incretins, in Phase [ADDRESS_790824] reported TEAEs for participants 
receiving LY 3437943  or dulaglutide were  nausea, vomiting, and diarrhea. To mitigate GI 
symptoms and manage participants with intolerable GI AEs, the investigator should:  
 Advise participants to eat smaller meals, for example, splitting 3 daily meals into 4, or 
more smaller meals, and to stop eat ing when they feel full. Also, participants may be 
informed that lower -fat meals could be better tolerated.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 42  If GI AEs occur, prescribe symptomatic medication (for example, anti -emetic or 
antidiarrheal medication) per local country availability and individu al participant needs. 
Use of symptomatic medication should be captured as concomitant medication in the 
eCRF.  
 Temporarily interrupt study drugs. The data related to temporary interruption of study 
treatment should be documented in source documents and ente red on the eCRF (see 
Section 6.6.1 ). 
 After the symptoms have resolved, restart dosing as per the guidance provided in Section 
6.6. 
If intolerable GI symptoms or events persist despi[INVESTIGATOR_10902] , see Section 6.6.1  
6.6. Dose Modification  
Study drug administration should follow the schedule provided in Section 1.3 (SoA) and Section 
4.1.1  (Overview of Study Periods ). Dose modification is not allowed, except for  
 temporary dose interruption to address tolerability or other clinically important safety 
issues , or 
 dose reductions, w ithout dosing interruptions, when appropriate to ensure participant 
safety.  
Any changes in dosing will be documented in the participant diaries and eCRF. Dose reductions 
may occur at unscheduled visits.  
6.6.1.  Temporary Interruption of Study Drug  
In certain situa tions , participants  may need to temporarily interrupt study drug , for example due 
to 
 occurrence of intolerable GI AEs, and  
 other AEs deemed by [CONTACT_597997].  
If the reason for temporary dosing interruption is  related to poor participant  tolerability, for 
example when protracted GI events of vomiting and/or diarrhea trigger a request from the 
participant and/or from the investigator for temporary discontinuation of dosing,  [ADDRESS_790825] be approved by [CONTACT_597998]. In other situations when 
participant  safety is compromised, for example due to an SAE, more than 1 dose may need to be 
skipped. The decision to interrupt dosing in any of these situations will not be considered a 
protocol deviation. If the participant  interrupts dosing for other reasons, that are not related to the 
tolerability or safety of the participant , dosing interrup tion will be considered a protocol 
deviation. Every effort should be made by [CONTACT_597999].  A participant  may experience multiple events that require dosing interruption; each event 
should be addressed in dividually per guidance provided in this section . Any other situation of 
study drug interruption that is not described in this section will be discussed between the primary 
investigator or designee and Lilly study physician to decide on an appropriate dosing plan for 
any participant  with such events.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790826] administered prior to 
interruption for 1 week and will then follow 
the planned dosing schedule.  
 If the rechallenge with LY3437943 is 
not tolerated, the dose will be reduced  
to the previously tolerated dose and 
the participant  will be kept  on that 
dose until the end of the treatment 
period.   
If the starting LY3437943 dose of 0.5 mg or 
2 mg or maintenance dose of 4 mg or 
dulaglutide 1.5 mg dose is not tolerated on 
rechallenge,  the participant  will discontinue 
study drug .  
If the starting LY3437943 dose of 4 mg is not 
tolerated upon rechallenge, the participant 
will be switched to the 2 mg starting dose, per 
the alternate dose escalation scheme.  
   
 2 or more 
consecutive 
doses  For participants on LY3437943, d osing will 
be restarted  on the previously tolerated, lower 
dose (that is, one dose level lower for that 
treatment arm than the dose that was not 
tolerated) for 2 weeks and then resume 
dosing per the planned dosing schedule.  
Participants in the dulaglutide group will be 
restarted on 1.5 mg dose.  
If the rechallenge with LY3437943 is  not 
tolerated  for a second time , the dose will be 
reduced to the previously tolerated dose and 
the participant  will be kept on that dose until 
the end of the treatment period.   
If the starting LY3437943 dose of 0.5 mg or 
2 mg, or maintenance dose of 4 mg or 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 44 Reason for 
Interruptions  Number of 
Doses Missed  Actions at Dosing Re-Initiation  
dulaglutide 1.5 mg is not tolerated upon 
rechallenge, the participant  will discontinue 
study drug .  
If the starting LY3437943 dose of 4 mg is no t 
tolerated upon rechallenge, the participant 
should be switched to the 2 mg starting dose, 
per the alternate dose escalation scheme.  
Other TEAEs  or 
reasons n ot related to 
TEAEs  (that is, due to a 
protocol deviation)  [ADDRESS_790827] administered prior to 
interruption for 1 week and then follow the 
planned dosing schedule.  
 2 or more 
consecutive 
doses  For participants on LY3437943, dosing  will 
be restarted  at one dose lower (for that 
treatment arm) than th e last dose 
administered prior to interruption; continue  
this dose for [ADDRESS_790828] dose level, restart 
dosing on that dose. Participants in the 
dulaglutide group will be restarted on 1.5 mg 
dose.  
Investigators should inform the sponsor that study drug has been temporarily interrupted. The 
data related to temporary interruption of study treatment will be documented in source 
documents and entered on the eCRF.  
6.6.2.  Dose Reductions Indicated to Ensure Participant  Safety  
In addition to the dose modifications described in Section 6.6, there may be situations when do se 
interruptions occur, where only dose reduction (without interrupting dosing) would be 
appropriate (for example, clinically significant changes in vital signs accompanied by [CONTACT_598000] a ctive treatments 
[LY3437943, dulaglutide] in the trial).   
If a participant is experiencing any such safety issue, dose reduction to the next lower 
maintenance dose level or discontinuation of study drug, if the participant is already on the 
lowest dose level, should be considered. The decision to lower the dose or discontinue study 
drug in such situation should be approved by [CONTACT_598001].  
All dosing modifications described in this section and in Section 6.6 will be conducted in a 
blinded fashion, by [CONTACT_598002]3437943 and dulaglutide as appropriate. 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 45 Participants will be blinded during dose modification. LY3437943 dose modificati on should 
occur together with temporary interruption of the dulaglutide SDP as described in Section 6.6.1 .  
6.7. Intervention after the End of the Study  
LY3437943  will not be made available to participants after conclusion of the study.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 46 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
7.1. Discontinuation of Study Intervention   
In rare instances, it may be necessary for a participant to permanently discontinue (definitive 
discontinuation) study intervention s. If study intervention s are definitively discontinued, the 
participant  will remain in the study to be evaluated for all planned efficacy and safety measures.  
See the SoA (Section 1.3) for data to be collected at the time of discontinuation of study 
intervention s and follow -up and for any further evaluatio ns that need to be completed . The 
participants will receive additional glucose -lowering agents if needed based on the investigator’s 
judgment  (see Section 6.5.1 . for detailed guidance).  
Possible reasons leading to permanent discontinuation of study drug : 
participant decision  
the participant requests to discontinue study drug  
clinical considerations  
BMI ≤ 19 kg/m2 
initiation of prohibited concomitant medications (see Section 6.5) if participants will not or 
cannot discontinue them  
intolerable GI symptoms despi[INVESTIGATOR_597966]  6.5.3  
Note:  The investigator should contact [CONTACT_92338] /Clinical research scientist 
(CRS ) to discuss whether it is medically a ppropriate for the participant to 
continue study treatment.  
diagnosis of T1DM  
diagnosis of MTC or MEN2 after randomization  
significant  elevation of calcitonin (serum calcitonin value ≥20 ng/L and <35 ng/L and ≥50% 
increase from the screening value; or s erum calcitonin value ≥35 ng/L and ≥50% over the 
screening value)  or diagnosis of C -cell hyperplasia  
diagnosis of acute or chronic pancreatitis  
diagnosis of an active or untreated malignancy (other than basal or squamous cell skin cancer, in 
situ carcinomas  of the cervix, or in situ prostate cancer) after randomization  
If the investigator, after consultation with the sponsor -designated medical monitor, determines 
that a systemic hypersensitivity reaction has occurred related to study drug administration, the  
participant should be permanently discontinued from the investigational drug  
onset of pregnancy in a female participant  
occurrence of any other TEAE, SAE, or clinically significant finding for which the investigator 
believes that permanent study  drug dis continuation is the appropriate measure to be taken  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 47  discontinuation due to a hepatic event or liver test abnormality  
o participants who are discontinued from study drug  due to a hepatic event or 
liver test abnormality should have additional hepatic safety da ta collected via 
eCRF  
o discontinuation of the study drug  for abnormal liver tests should be  
considered by [CONTACT_82378] a participant meets one of the following 
conditions after consultation with the Lilly -designated medical monitor:  
 ALT or aspartat e aminotransferase (AST) >8X ULN  
 ALT  >2X baseline value (for participants with elevated 
ALT levels at baseline) OR ≥300  U/N, whichever occurs 
first, if baseline ALT  ≥2X ULN  
 ALT or AST >5X ULN for more than 2 weeks  
 ALT or AST >3X ULN and total bilirubin level (TBL) >2X 
ULN or international normalized ratio (INR) >1.5  
 ALT or AST >3X ULN with the appearance of fatigue, 
nausea, vomiting, right upper -quadrant pain or tenderness, 
fever, rash, and/or eosinophilia (>5%)  
 alkaline phosphatase (ALP) >3X ULN  
 ALP >2.5X ULN and TBL >2X ULN  
 ALP >2.5X ULN with the appearance of fatigue, nausea, 
vomiting, right -quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%).  
7.2. Participant Discontinuation/Withdrawal from the Stud y 
A participant may withdraw from the study:  
 at any time at his  or her own request  
 at the request of his  or her designee (for example, parents or legal guardian)  
 at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
 if the participant becomes pregnant during the study  
 if enrollment in any other clinical study involving an investigational product 
or enrollment in any other type of medical research judged not to be 
scientifically or medically compatible with th is study  
 if the participant, for any reason, requires treatment with another therapeutic 
agent that has been demonstrated to be effective for treatment of the study 
indication, discontinuation from the study occurs prior to introduction of the 
new agent.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 48 At the time of discontinuing from the study, if possible, an ED visit should be conducted. See 
SoA (Section 1.3) for data to be collected at the time  of study discontinuation and follow -up and 
for any further evaluations that need to be completed. The participant will be permanently 
discontinued both from the study intervention and from the study at that time.  
If the participant withdraws consent for d isclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. If a participant 
withdraws from the study, he  or she may request destruction of any samples taken and not tested, 
and the in vestigator must document this in the site study records.  
7.3. Lost to Follow -Up 
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. Site personnel or d esignee are 
expected to make diligent attempts to contact [CONTACT_10971] a scheduled visit 
or were otherwise unable to be followed up by [CONTACT_779].   
Discontinuation of specific sites or of the study as a whole are handled as part of Sec tion 10.1 
Appendix 1.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 49 8. Study Assessments and Procedures  
 Study procedures and their timing are summarized in the SoA.  
 Immediate safety concerns should be discussed with the sponsor immediately 
upon occurrence or awareness to determine if the participant should continue 
or discontinue study intervention.  
 Adherence to the study design requirements, including those specified in the 
SoA, is essential and req uired for study conduct.  
 All screening evaluations must be completed and reviewed to confirm that 
potential participants meet all eligibility criteria. The investigator will 
maintain a screening log to record details of all participants screened and to 
confirm eligibility or record reasons for screening failure, as applicable.   
8.1. Efficacy Assessments  
Primary:  
The primary efficacy measure is change from baseline in HbA1c, as determined by [CONTACT_11378].  
Secondary:  
The following secondary efficacy  measures will be collected at the times shown in  the SoA . 
 HbA 1c as determined by [CONTACT_2237]  
 Fasting blood glucose (FBG ) as determined by [CONTACT_2237] , and  
 Body weight  (see Section 10.9 for measurement procedure) . 
Exploratory:  
 Seven -point SMBG (see Section 10.9)  
Lipid pr ofile, consisting of total cholesterol, low-density lipoprotein (LDL) -cholesterol, 
very low -density lipoprotein (VLDL) -cholesterol, high-density lipoprotein (HDL) -
cholesterol, and triglycerides  
Mechanistic biomarkers: to explore potential mechanism of acti on modifying glucose, 
lipid, or nutrient metabolism, markers will be assessed (see Section 10.[ADDRESS_790829] 
of biomarkers)  related to  
insulin sensitivity  
pancreatic beta or alpha cell function  
glucagon receptor target engagement   
fatty acid oxidation  
lipolysis  
purine metabolism , and  
cardiovascular risk . 
Patient -reported outcomes  (see Section 10.10 )  
Short Form -36 version 2 Health Survey acute form, 1 -week recall version  
Eating Inventory , and  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790830] circumference  should be 
conducted according to S oA, and following the study -specific recommendations included in  
Section 10.9.  
A complete physical examination will include, at a minimum, assessments of  
skin, including feet  
cardiovascular ( CV) 
respi[INVESTIGATOR_597967] l systems   and 
thyroid exam.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
8.2.2.  Vital Signs  
For each participant, vital sign measurements should be conducted according to S oA, and 
following the study -specific recommendations included in Section 10.9. 
Any clinically significant findings from vital sign measurement that result in a diagnosi s and  that 
occur after the participant receives the first dose of study intervention should be reported to  Lilly 
or its designee as an AE via eCRF.  
8.2.3.  Electrocardiograms  
For each participant, a single  12-lead ECG should be collected according to Section 1.3 (for 
details , please see Section 10.9. In addition, tracings collected at the baseline, [ADDRESS_790831] of clinical laboratory tests to be performed and to the 
SoA for the timing and frequency.  
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790832] be retained with source documents unless a Source 
Document Agreement or c omparable document cites an electronic location that 
accommodates the expected retention duration. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, 
unless judged by [CONTACT_2418] m ore severe than expected for the 
participa nt’s condition.  
 All laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within [ADDRESS_790833] collection 
requirements, and laboratory manual.  
 If laboratory values from non -protocol -specified laboratory assessments 
performed at an investigator -designated local laboratory require a change in 
participant management or are considered clinically significant by [CONTACT_1275] (for example , SAE or AE or dose modification), then rep ort the 
information as an AE.  
8.2.5.  Safety Monitoring  
Lilly will periodically review evolving aggregate safety data within the study by [CONTACT_81132]. The study team will review safety reports in a blinded fashion  (for applicable blinded 
study period)  according to the schedule provided in the Trial -Level Safety Review plan. Lilly 
will also review SAEs within time frames mandated by [CONTACT_10984].  The Lilly CRP 
will, as appropriate, consult with the functionally independent Global Patient Safety (GPS)  
therapeutic area physician or clinical scientist . Safety monitoring will include review of hepatic, 
pancreatic, cardiovascular, thyroid c -cell function , and renal safety data. The hepatic safety 
monitoring plan is provided below ; for additional information , please see also Section 8.3.2 . 
[IP_ADDRESS].  Hepatic Safety Monitoring  
Close hepatic monitoring  
If any of the  following  abnormalities occur red, l aboratory tests (Section 10.5), including ALT, 
AST, ALP, TBL , direct bilirubin , gamma -glutamyltransferase , and creatine kinase , should be 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 52 repeated within 48 to 72  hours to confirm the abnormality and to determine if the va lues are  
increasing or decreasing :  
If a participant with baseline results 
of… develops the following elevations:  
ALT or AST <1.[ADDRESS_790834] ≥[ADDRESS_790835]  
ALP <1.[ADDRESS_790836]  ALP ≥[ADDRESS_790837]  
TBL <1.[ADDRESS_790838]  TBL ≥[ADDRESS_790839] (except for p articipants  with 
Gilbert’s syndrome)  
ALT or AST ≥1.[ADDRESS_790840] ≥2 X baseline  
ALP ≥1.[ADDRESS_790841]  ALP ≥2 X baseline  
TBL ≥1.[ADDRESS_790842]  TBL ≥ 1.5X  baseline (except for p articipants  
with Gilbert’s syndrome)  
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by [CONTACT_61520] -designated medical monitor. At a minimum, this eval uation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including OTC ), herbal and dietary supplements, history of alcohol drinking , and 
other substance abuse.   
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical condition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be reduced  to once every 1 to 2 weeks, if the 
participant’s clinical condition and lab results stabilize. Monitoring of ALT, AST, ALP, and 
TBL should continue until levels normalize o r return to approximate baseline levels . 
Comprehensive hepatic evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
1 or more of these conditions occur:  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 53 If a participant with baseline results of…  develops the following elevations:  
ALT or AST <1.[ADDRESS_790843] ≥[ADDRESS_790844] with hepatic signs  or 
symptoms*, or  ALT or AST ≥[ADDRESS_790845]  
ALP <1.[ADDRESS_790846]  ALP ≥[ADDRESS_790847]  
TBL <1.[ADDRESS_790848]  TBL ≥ 2X ULN (except for p articipants  with 
Gilbert’s syndrome)  
ALT or AST ≥1.5X ULN  ALT or AST ≥2 X baseline with hepatic signs  or 
symptoms*, or ALT or AST ≥3 X baseline  
ALP ≥1.[ADDRESS_790849]  ALP ≥2 X baseline  
TBL ≥1.[ADDRESS_790850]  TBL ≥ 2X baseline (except for pa rticipants with 
Gilbert’s syndrome)  
* Hepatic signs  or symptoms are severe fatigue, nausea, vomiting, jaundice, right upper quadrant abdominal pain, 
fever, rash, and/or eosinophilia >5%.  
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as wel l as tests for prothrombin time ( PT)-INR; tests for viral 
hepatitis  A, B, C, or E; tests for autoimmune hepatitis; and an abdominal imaging study (for 
example, ultrasound or computed tomography [ CT] scan).  
Based on the p articipan t’s history and initial re sults, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for hepatitis D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxicology screen,  Wilson’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
blood phosphatidylethanol. Based on the circumstances and the investigator’s assessment of the 
participant’s clinical condition, the investigator should consider referring the particip ant for a 
hepatologist or gastroenterologist consultation, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.  
Additional hepatic data collection (hepatic safety CRF) in st udy participants who have 
abnormal liver tests during the study  
Additional hepatic safety data collection in hepatic safety CRFs should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum ALT to ≥[ADDRESS_790851]  on 2 or more consecutive blood tests (if baseline 
ALT <1.[ADDRESS_790852])  
 In participants with baseline ALT ≥1.[ADDRESS_790853], the threshold is ALT ≥3 X baseline on 
2 or more consecutive tests  
2. Elevated TBL to ≥ [ADDRESS_790854] (if baseline TBL <1.[ADDRESS_790855]) (except for cases of know n 
Gilbert’s syndrome)  
In participants with baseline TBL ≥1.[ADDRESS_790856], the threshold should be TBL  ≥2X baseline  
3. Elevation of serum ALP to ≥[ADDRESS_790857] on 2 or more consecutive blood tests (if baseline 
ALP <1.[ADDRESS_790858])  
 In participants with baseline ALP ≥1.[ADDRESS_790859], the threshold is ALP ≥2 X baseline on 
2 or more consecutive blood tests  
4. Hepatic event considered to be a n SAE  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 54 5. Discontinuation of study drug due to a hepatic event .  
Note:  The interval between the [ADDRESS_790860] Complaints  
The definitions of the following events can be found in Section 10.3 Appendix 3.   
 AEs 
 SAEs , and  
 Product complaints (PCs) . 
These events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, 
or the participant ’s legally authorized representative).  
The investigator and any qualified designees are responsible fo r detecting, documenting, and 
recording events that meet these definitions and remain responsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the  study (see Section  7). 
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal questioning of the particip ant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs, and AEs of special interest , will be followed until 
resolution, stabilization, the event is otherwise explained, or the participant is lost to follow -up 
(as defined in Section 7.3). For PCs, the investigator is responsible for ensuring that follow -up 
includes any supplemental investigations as indicated to elucidate the nature and/or causality.  
Further information on follow -up procedures is provided in Appendix  10.3. 
8.3.1.  Timing and Mechanism for Collecting Events  
The following table describes the timing, deadlines, and mechanism for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing  for Reporting to 
Sponsor or Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
Adverse Event  
AE Signing of 
the ICF  Participation 
in study has 
ended  As soon as possible upon site 
awareness  AE eCRF  N/A 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 55 Event  Collection 
Start  Collection 
Stop  Timing  for Reporting to 
Sponsor or Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
Serious Adverse Event  
SAE and SAE 
updates – prior 
to start of study 
intervention 
and deemed 
reasonably 
possibly 
related with 
study 
procedures  Signing of 
the ICF  Start of 
intervention  Within 24 hours of 
awareness  SAE eCRF  SAE paper 
form  
SAE * and SAE 
updates  – after 
start of study 
intervention  Start of 
intervention  Participation 
in study has 
ended  Within 24 hours of 
awareness  SAE eCRF  SAE paper 
form  
SAE*  – after 
participant’s 
study 
participation 
has ended and 
the investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in 
female 
participants 
and female 
partners of 
male 
participants  After the 
start of study 
intervention  [ADDRESS_790861] led 
to an SAE  Start of 
study 
intervention  End of 
study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 56 Event  Collection 
Start  Collection 
Stop  Timing  for Reporting to 
Sponsor or Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
PC not 
associated with 
an SAE  Start of 
study 
intervention  End of 
study 
intervention  Within 1 business day of 
awareness  PC form  N/A 
Updated PC 
information  — — As soon as possible upon site 
awareness  Originally 
completed P C 
form with all 
changes signed 
and dated by [CONTACT_1275]  N/A 
PC (if 
investigator 
becomes 
aware)  Participation 
in study has 
ended  N/A Promptly  PC form   
Abbreviations: AE  = adverse event; eCRF  = electronic case report form; N/A  = not applicable; PC  = product 
complaint; SAE  = serious adverse events . 
*Serious adverse events, including death, caused by [CONTACT_382626] . 
8.3.2.  Adverse Events of Special Interest  
The following are adverse events  that will be adjudicated by [CONTACT_10988]:  
 pancreatitis (see Section [IP_ADDRESS] ) 
 major adverse cardiovascular events (see Section  [IP_ADDRESS] ), and  
 deaths . 
The following are additional adverse events of special interest :  
 hypoglycemia (Level 2 and 3)  
 severe persistent hyperglycemia  
 thyroid malignancies and C -cell hyperplasia  
 CV safety  
 hypersensitivity events  
 injection site reactions  
 hepatobiliary disorders  
 severe GI AEs  
 antidrug antibodies , and  
 acute renal events . 
Sites should collect additional details and data regarding these adve rse events , as instructed on 
the applicable eCRFs, and detailed below.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 57 [IP_ADDRESS].  Hypoglycemia  
Upon ICF signing, all participants will be educated about signs and symptoms of hypoglycemia,  
how to treat hypoglycemia, and how to collect appropriate information for eac h epi[INVESTIGATOR_10918].  
Participants who develop persistent or recurrent unexplained hypoglycemia during the treatment 
period will be asked to reduce the dose or discontinue any concomitant glucose -lowering agents 
other than study drug. Study drug discontinuation for recurrent hypoglycemia should be 
considered only if these events continue despi[INVESTIGATOR_597968].  
All hypoglycemic epi[INVESTIGATOR_134055] a specific eCRF and should not be recorded as 
AEs unless the event meets serious criteria. If a hypoglycemic event meets severe criteria (see 
definition below), it should be recorded as serious on the AE and SAE eCRFs, and reported to 
Lilly as an SAE.  
Investigators should use the following definitions and  criteria when diagnosing and categorizing 
an epi[INVESTIGATOR_10920] (the BG values in this section refer to values 
determined by a laboratory or International Federation of Clinical Chemistry and Laboratory 
Medicine blood -equival ent glucose meters and strips) in accordance with the 2020 American 
Diabetes Association position statement on glycemic targets  (ADA 2020)  as below. Level [ADDRESS_790862] : 
Level 1 hypog lycemia:  
Glucose <70 mg/dL (3.9 mmol/L) and ≥ 54 mg/dL (3.0 mmol/L):  Level [ADDRESS_790863] -acting carbohydrates. Providers 
should continue to counsel partic ipants to treat hypoglycemia at this g lucose alert value.  
Level 2 hypoglycemia:  
Glucose <54 mg/dL (3.0 mmol/L):  This is  also referred to as documented or blood glucose 
confirmed hypoglycemia  with glucose <54 mg/dL (3.0 mmol/L). This glucose threshold is 
clinically relevant regardless of the presence of absence of symptoms of hypoglycemia.  
Level 3 hypoglycemia:  
Severe hypoglycemia (in adults): A severe event characterized by [CONTACT_598003] d/or 
physical status requiring assistance for treatment of hypoglycemia. For example, p articipants  
had altered  mental  status,  and could not assist in their own care, or were  semiconscious or 
unconscious, or experienced  coma  with or without  seizures,  and the assistance of another 
person was needed to actively administer carbohydrate, glucagon, or other resuscitative  
actions.  Glucose  measurements  may not be available during  such an event, but neurological 
recovery  attributable to the restoration of  glucose concentration  to normal  is considered  
sufficient  evidence  that the event was induced by  a low glucose concentration.  
 The determination of a hypoglycemic event as an epi[INVESTIGATOR_66677], as 
defined above, is made by [CONTACT_598004] a 
participant simply having received assistance.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 58  If a hypoglycemic event meets the criteria of severe hypoglycemia, the investigator 
must record the event as  serious on the AE CRF and report it to Lilly as an SAE.  
Nocturnal hypoglycemia : 
Nocturnal hypoglycemia is  a hypoglycemia event (including severe hypoglycemia) that 
occurs at night  and presumably during sleep.  
[IP_ADDRESS].  Severe Persistent Hyperglycemia  
An additional glucose -lowering  intervention should be considered by [CONTACT_598005], defined as meeting any of the following 
criteria during the treatment period :  
During the first 8 weeks postrandomization ( between Visit s 3 and 7 ): An average fasting blood  
glucose (FBG) above 255 mg/dL (14.1 mmol/L) over at least a 2 -week period (at least 4 
values/week must be available)  
OR 
Between Week s 8 and 16 (between Visits 7 and 9): An average F BG above  240 mg/dL (13.3 
mmol/L) over at least a 2 -week period (at least 4 values/week must be available)  
OR 
Between Week s 16 and 24 (between Visits 9 and 11): An average F BG above  200 mg/dL (11.1 
mmol/L) over at least a 2 -week period (at least 4 values/week must be available  
OR 
Beginning at Week 24 (Visits 11 through 13): HbA1c above 8.0% (64.0 mmol/mol) which is not 
at least 0.3% lower than the HbA1c at the previous scheduled measurement . 
In considering whether initiation of rescue therapy is warranted, investiga tors should first 
confirm that the p articipant  is fully compliant with the assigned therapeutic regimen and that he  
or she does not have an acute condition causing severe hyperglycemia. If these other reasons are 
excluded, the investigator will initiate an  appropriate glucose -lowering intervention (rescue 
intervention) according to the guidance outlined in Section 6.5, and it will be recorded on the 
eCRF specified for collecting antihyperglycemic medications. Other GLP -[ADDRESS_790864] not be used as the rescue intervention.  Participants  who receive rescue 
intervention for hyperglycemia management should also continue administering study d rug for 
the remaining period in the trial.  
[IP_ADDRESS].  Pancreatitis  
Diagnosis of acute pancreatitis  
Acute pancreatitis is an AE of interest in all studies with  LY3437943 , including this study. The 
diagnosis of acute pancreatitis requires 2 of the following 3 features  (Banks and Freeman 2006 ; 
Kouzumi 2006):  
 abdominal pain, characteristic of acute pancreatitis (that is, epi[INVESTIGATOR_291577], often associated with nausea and vomiting)  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 59  serum amylase (total, pancreatic, or both) and/or lipase ≥3X ULN , and  
 characteristic findings of acute pancreatitis on CT scan or magnetic resonance imaging 
(MRI).  
If acute pancreatitis is suspected, the investigator should  
 obtain appropriate laboratory tests, including pancreatic amylase and lipase  
 perform imaging studies,  such as abdominal CT scan with or without contrast, or 
abdominal MRI , and  
 evaluate for possible causes of acute pancreatitis, including alcohol use, gallstone  or gall 
bladder disease, hypertriglyceridemia, and concomitant medications.  
Discontinuation for acute pancreatitis  
If acute pancreatitis is suspected  by [CONTACT_093] , the participant must temporarily discontinue 
use of the IP. In this case, the participant  needs to receive an appropriate alternative glucose 
lowering regimen . Afterwards, if pancreatitis  is confirmed by [CONTACT_247664], the IP 
must be permanently discontinued and the participant  needs to be followed throughout the 
duration of the study. If the case is not confirmed, then the participant can restart the IP if the 
investigator deems as clinically appropriate as described in Section 6.6 (Dose Modification) . 
Case adjudication and data entry  
An independent clinical endpoint committee (CEC) will adjudicate all suspected cases of acute 
pancreatitis. Relevant data from participants with acute pancreatitis will be entered into a 
specifically designed  eCRF page. The adjudication committee representative will enter the 
results of adjudication in a  corresponding eCRF page.  
Asymptomatic elevation of pancreatic  amylase and/or lipase  
Serial measures of pancreatic enzymes have limited clinical value for predicting epi[INVESTIGATOR_37455] i n asymptomatic participant s (Nauck et al. 201 7; Steinberg et al. 2017a, 
2017b). Therefore, further diagnostic follow -up of cases of asymptomatic elevation of pancreatic 
enzymes (lipase and/or p ancreatic amylase ≥3X ULN) is not mandated but may be performed  
based on the investigator’s clinical judgment and assessment of the participant’s overall clinical 
condition.   
[IP_ADDRESS].  Thyroid Malignancies and C -Cell Hyperplasia  
Individuals with personal or family history of MTC and/or MEN2 will be excluded from the 
study. Par ticipants who are diagnosed with MTC and/or MEN2 during the study will have study 
drug stopped and should continue follow -up with an endocrinologist. Additionally, participants 
who have a serum calcitonin level of ≥20 ng/L, if eGFR ≥ 60 mL/min/1.73 m2 or ≥35 ng/L if 
eGFR < 60 mL/min/1.73 m2, as determined by [CONTACT_82408] 1, will also be 
excluded.  
The assessment of thyroid safety during the trial will include reporting of any case of thyroid 
neoplasms  (including MTC , papi[INVESTIGATOR_10928] , and o thers ) and measurements of calcitonin. 
These  data will be captured in specific eCRFs. The purpose of calcitonin measurements is to 
assess the potential of LY3437943  to affect thyroid C -cell function, which may indicate 
development of C -cell hyperplasia and  neoplasms.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 60 If an increased calcitonin value  (see definitions below) is observed in a participan t who has been 
administered a medication that is known to increase serum calcitonin , then  this medication 
should be stopped , and calcitonin levels should be measured after an appropriate washout period.  
For participan ts who require additional endocrine assessment because of increased calcitonin 
concentration as defined  in this section, data from the follow -up assessment will be  collected in 
the specific section of the eCRF.  
Calcitonin Measurements in Participants with eGFR ≥60 mL/min /1.73 m2  
A significant increase in calcitonin for participants with eGFR ≥60 mL/min/1.73 m2 is defined 
below. If a participant ’s lab oratory results  meet th ese criteria, these clinically significant 
laboratory results  should be recorded as an AE.  
 Serum calcitonin value ≥20 ng/L and <35 ng/L AND ≥50% increase from the screening 
value.  These participants will be requested to repeat the measurement with in 1 month. If 
this repeat value is increas ing (≥10% increase), the study drug should be discontinued, 
and the participant  should  undergo additional endocrine assessment and longer  term 
follow -up by [CONTACT_598006] . 
 Serum calcitonin value ≥35 ng/L AND ≥50% over the screening value . In these 
participants , study drug should be discontinued, and the participant  should be 
recommended to immediately undergo additional endocr ine assessments and longer term 
follow -up by [CONTACT_598007].   
Calcitonin Measurement in Participants with eGFR <60 mL/min /1.73  m2  
A significant increase in calcitonin for participants with eGFR <60  mL/min /1.73  m2 is defined as 
a serum calcitonin value ≥35 ng/L AND ≥50% over the screening value. If a participant ’s labs 
meet th ese criteria, these clinically significant labs should be recorded as an AE.  
In these participants, if  the increased concentration of calcitonin is confirmed , the participant 
must be recommended to immediately undergo  additional endocr ine assessments and longer -
term follow -up by [CONTACT_598008] .  
[IP_ADDRESS].  Major Adverse Cardiovascular Events  
Nonfatal cardiovascular  AEs will be adjudicated by a committee of physicians external t o Lilly 
with cardiology expertise. This committee will be blinded to treatment assignment. The nonfatal 
cardiovascular  AEs to be adjudicated include  
 myocardial infarction  
 hospi[INVESTIGATOR_10929]  
 hospi[INVESTIGATOR_19934]  
 coronary inter ventions (such as coronary artery by[CONTACT_598009]), and  
 cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 61 [IP_ADDRESS].  Supraventricular A rrhythmias and Cardiac Conduction Disorders   
Treatment -emergent cardiac conduction disorders will be further evaluated.  Participants  who 
develop any event from these groups of disorders should undergo an ECG , which should be 
submitted to the central reading center.  Additional diagnostic tests to dete rmine exact diagnosis 
should be performed, as needed.  The specific diagnosis will be recorded as an AE. Events that 
meet criteria for serious conditions as described in Section  10.[ADDRESS_790865]  be reported as SAEs.  
[IP_ADDRESS].  Deaths  
All deaths will be adjudicated by a committee of physicians external to Lilly. This committee 
will be blinded to treatment assignment.  
[IP_ADDRESS].  Hypersensitivity Reactions   
Many drugs, particularly  biologic agents , carry the ri sk of systemic hypersensitivity reactions.  If 
such a reaction occurs, a dditional data describing each symptom should be provide d to the 
sponsor in  the eCRF.  
Sites should have appropriately trained medical staff and appropriat e medical equipment 
available when study participants  are receiving study drug . It is recommended that participants  
who experience a  systemic hypersensitivit y reaction be treated per  national and international 
guidelines.  
In the case of generalized urticar ia or anaphylaxis , additiona l blood and urine samples should be 
collected as described in Section 10.2. Laboratory results are provided to the sponso r via the 
central laboratory.  
[IP_ADDRESS].  Injection S ite Reactions  
Symptoms of a local injection site reaction (ISR) may include erythema, induration, pain, 
pruritus, and edema. If an injection site event is reported, the AE will be recorded, a nd additional 
data will be provided to the sponsor in the eCRF. At the time of occurrence  of severe or serious 
ISRs , samples will be collected for measurement of LY3437943  antidrug antibodies (ADAs) and 
LY3437943 concentration . 
[IP_ADDRESS].  Hepatobiliary Disorders  
All e vents of TE biliary colic, cholecystitis, or other suspected events related to gallbladder 
disease should be evaluated and additional diagnostic tests performed, as needed.  In cases of 
elevated liver markers, hepatic monitoring should be initiated as outli ned in Section [IP_ADDRESS] . 
[IP_ADDRESS].  Severe Gastrointestinal Adverse Events  
LY3437943 and dulaglutide may cause severe GI AEs, such as nausea, vomiting, and diar rhea. 
Information about severe GI AEs as well as antiemetic  or antidiarrheal use will be collected in 
the AE and concomitant medications e CRF s, respectively.  For detailed information concerning 
the management of GI AEs, please refer to Section  6.5.3 . 
[IP_ADDRESS].  Acute Renal Events  
Renal safety will be assessed based on repeated renal functional assessment as well as 
assessment of AEs suggestive of acute  renal failure or worsening of preexisting chronic renal 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790866] been reported with LY3437943 , including nausea, diarrhea, 
and vomiting.  This is consistent with other GLP -1R agonists (Aroda and Ratner 2011). The 
events may lead t o dehydration, which could cause a deterioration in renal function, including 
acute renal failure.  Participants  should be advised to notify investigators in case of severe nausea, 
frequent vomiting, or symptoms of dehydration.  
8.4. Treatment of Overdose  
For thi s study, any total dose of study intervention  within a 48-hour time period greater than the 
dose assigned by [CONTACT_598010] 10.3. 
In the event of an overdose , the investigator should 
1. Contact [CONTACT_27465].  
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities until study 
intervention  can no longer be detected systemically (at least  30 days). Refer to Section 
8.[ADDRESS_790867] dose of 
study intervention if requested by [CONTACT_1689] (determined on a case -by-case 
basis) . 
Decisions regarding d ose interruptions or modifications will be made by [CONTACT_598011] .  
In the event of overdose, refer to the IB for the study drug and/or product label  for Trulicity 
(dulaglutide), as applicable.  
8.5. Pharmacokinetics  
Blood samples for PK analyses will be collected from all randomized participants in accordance 
with schedule provided in Section 1.3 and at E D. Efforts should be taken to align clinical visits 
with PK sampling windows specified in the Pharmacokinetic Schedule of Events table (Section 
1.3). Otherwise,  participants may need to return to the clinical site for additional PK-specific 
visits to provide PK samples. Only samples from participants assigned to treatment with 
LY3437943 will be analyzed for drug concentration.   
Date and time of each sample and the most recent LY3 [ADDRESS_790868] participant  visit for the study. During this time, samples remaining after the bioanalyses may 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 63 be used for exploratory analyses such as additional metabolism , protein binding , or exploratory 
analyses including bioanalytical assay validation or cross -validation exercises.  
8.6. Pharmacodynamics  
Pharmacodynamic assessments for LY 3437943  are included as part of the efficacy and safety 
measures listed in Section 8.1 and will be collected according to the SoA (Section 1.3). 
8.7. Genetics   
A blood  sample will be collected to enable exploratory  pharmacogenetic analys es as specified in 
the S oA (Section  1.3), where local regulat ions allow.  
Samples will not  be used to conduct unspecified disease or population genetic research either 
now or in the future. Samples may be used to investigate variable exposure or response to  
LY3437943  and to investigate genetic variants thought to pla y a role in  diabetes mellitus and 
related clinical traits or complications, including nonalcoholic steatohepatitis or obesity . 
Assessment of variable response may include evaluation of AEs or differences in 
pharmacodynamic, mechanistic, safety, or efficacy  measures .  
All samples will be coded with the participant  number. These samples and any data generated 
can be linked back to the participant  only by [CONTACT_41417].  
Samples will be retained for a maximum of [ADDRESS_790869]  participant  visit, or for a 
shorter period if local regulations and/or the Ethical Review Board ( ERB ) impose shorter time 
limits, for the study at a facility selected by [CONTACT_81278].  This retention period enables 
use of new technologies, response  to regulatory questions, and investigation of variable response 
that may not be observed until later in the development of LY3437943 or after LY3437943  is 
commercially available.  
Molecular technologies are expected to improve during the 15 -year storage p eriod and therefore 
cannot be specifically named. However, existing approaches include whole -genome  or exome 
sequencing, genome -wide association studies, multiplex assays, and candidate gene studies . 
Regardless of technology utilized, data generated will b e used only for the specific research 
scope described in this section . 
8.8. Biomarkers  
In addition to the planned biomarker research as indicated in the SoA and Section 10.11 , 
biomarker research on stored nonpharmacogenetic samples  may be  performed to address 
questions of relevance to  drug disposition, target engagement, pharmacodynamics , mechanism of 
action, variability of participant response (including safety), and clinical outcome. Sample 
collection is incorporated into clinical studies to enable examination of these questions through 
measurement of biomolecules , including DNA, RNA, proteins, lipi[INVESTIGATOR_805], and other cellular 
elements .  
Serum and plasma sample s for nonpharmacogenetic biomarker research will be collected at the 
times specified in the SoA (Section  1.3) where local regulations allow.  
 
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790870] participant vis it for the study, or for a shorter period if local regulations and ERBs 
impose shorter time limits.  This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed unt il later 
in the development of  LY3437943  or after LY3437943  becomes commercially available.  
8.9. Immunogenicity Assessments  
At the visits and times specified in the SoA (Section  1.3), blood  samples will be collected to 
determine antibody production against LY3437943 . Antibodies may be further characterized for 
cross -reactive binding to endogenous counterparts (native GIP , GLP -1, and glucagon), and their 
ability to neutralize the activity of LY3437943  and endogenous counterparts. To interpret the 
results of immunogenicity,  a blood sample will be collected at  the same time points  to determine 
the concentrations of LY3437943 . All samples for immunogenicity should be taken predose 
when applicable and possible.  
Treatment -emergent ADAs are defined in Section 9.4.[ADDRESS_790871] 
scheduled assessment or discontinuation visit is TE -ADA positive, additional samples may be 
taken until the signal returns to baseline ( in other words , no longer indicates TE-ADA)  or for up 
to [ADDRESS_790872] dose. A PK sample may be collected at each time point at the investigator’s 
discretion.  
Samples will be retained for a maximum of [ADDRESS_790873] participant visit, or for a 
shorter peri od if local regulations and E thical Review Boards  allow,  at a facility selected by [CONTACT_103]. The duration allows the sponsor to respond to future regulatory requests related to the 
LY3437943 . Any samples remaining after 15 years will be destroyed.  
8.10. Healt h Economics  
This section is not applicable for this study.  
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790874] one of LY3437943 doses is superior to placebo and 
dulaglutide 1.5 mg with regards to  
 change in HbA1c from baseline to 24 and 36 weeks except comparison with placebo at 
24 weeks  (primary objective)  
 percentage of participants reaching HbA1c of  <7.0% at 24  and/or 36 weeks  
 change in FBG from baseline to 24 and 36 weeks , and  
 change in body weight (kg) from baseline to 24 and 36 weeks . 
9.2. Sample Size Determination  
Approximately 300 participants will be  randomized in a 2:2:2:1:1:1:1:2 ratio to either  placebo, 
dulaglutide 1.5  mg, LY3437943  0.5 mg, LY3437943  4 mg (with starting dose at 2  mg), 
LY3437943  4 mg (with starting dose at 4  mg), LY3437943 8 mg (with starting dose at 2  mg), 
LY3437943 8 mg (with starting dose at 4  mg), or LY3437943  12 mg (with starting dose  at 2 
mg). Assuming a 20% dropout rate , this  result s in approximately [ADDRESS_790875]. The LY3437943  group mean 
reduction in HbA1c at Week 24 from bas eline compared to placebo  is assumed to be -2.1% 
assuming a common standard deviation (SD) of 1.1% . The chosen sample size provides  at least  
99% power to establish superiority of LY3437943  0.5 mg, LY3437943  4 mg , LY3437943 8 mg, 
or LY3437943  12 mg compared  to placebo.  No adjustment for multiplicity will be performed.  
9.3. Populations for Analyses  
The following populations are defined  for the purpose of analysis : 
Population  Description  
Screened  All participants who have signed informed consent . 
Randomized  All participants who are randomly assigned to a treatment arm.  
Efficacy analysis set (EAS)  All randomized participants who take at least 1 dose of double -blind ed study 
treatment from randomization . Excludes data after discontinuation of study 
drug or initiation of rescue medication . Participants will be included in the 
treatment group to which they were randomized.  
Full analysis set (FAS)  All randomized participants who take at least 1 dose of double -blind ed study 
treatment, regardless of adherenc e to study drug or initiation of rescue 
medication . Participants will be included in the treatment group to which they 
were randomized.   
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 66 9.4. Statistical Analyses  
9.4.1.  General Considerations  
Statistical analyses of this study will be the responsibility of Lilly or its designee.  
Any change to the data analyses methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to data analyses 
methods described in the protocol, and the justification for  making the change, will be described 
in the statistical analysis plan (SAP) or the clinical study report (CSR). Additional exploratory 
analyses of the data will be conducted as deemed appropriate.  
Unless otherwise noted, all tests of treatment effects wil l be conducted at a 2 -sided alpha level of 
0.05, and the confidence interval (CI) will be calculated at 95%, [ADDRESS_790876] in comparing efficacy of LY3437943 doses with placebo for 
this study is the “efficacy estimand ,” which represents the efficacy prior to dis continuation of 
study drug without confounding effects of antihyperglycemic rescue therapy. The primary 
efficacy assessment, guided by [CONTACT_941] “efficacy estimand ,” will be conducted using the EAS. The 
“treatment -regimen estimand ,” using the FAS, which represen ts the efficacy irrespective of 
adherence to study drug or initiation of rescue antidiabetic drug, and the “principle -stratification 
estimand” that shows  efficacy  for those who would  comply with  the study treatment LY3437943 
(as defined in Section [IP_ADDRESS] ) will be estimated in the exploratory analyses . 
The summary statistics for continuous measures will include sample size, mean, SD, median, 
minimum, an d maximum, and for categorical measures will include sample size, frequency, and 
percentage. The analysis model to make comparisons among treatment groups relative to 
continuous measurements assessed over time (in addition to the baseline and end of treatm ent 
measurements) will be a mixed model for repeated measures (MMRM) with terms:  
treatment  
visit  
treatment -by-visit interaction  
baseline HbA1c category [<8.5% or 8.5%]  
baseline BMI category [<30 or 30], and  
baseline measurement as a covariate.  
Summary statistics for categorical measures (including categorized continuous measures) will 
include sample size, frequency, and percentages. Fisher’s exact test will be used to examine the 
treatment difference in categorical outcomes. Logistic regression may be used to examine the 
treatment difference in binary efficacy outcomes. The negative binomial regression model will 
be used for the treatment comparison of discrete count measures if deemed appropriate.  
Other statistical methods may be used, as appro priate, and details will be documented in the 
SAP.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 67 9.4.2.  Treatment Group Comparability  
[IP_ADDRESS].  Participant  Disposition  
Frequency counts and percentages of all participants  screened, randomized, and receiving at least 
1 dose of study drug will be presented by [CONTACT_3148] g roups. A listing of randomized participants  
not receiving study drug will be provided.  All participants who discontinue the study will be 
identified, and the extent of their participation in the study will be reported. If known, a reason 
for their disconti nuation will be given. The  primary reasons for discontinuation will be listed and 
will be summarized by [CONTACT_3148]. The  percentage of participants  discontinuing from each 
treatment will be compared using the Fish er’s exact test.  A Kaplan -Meier analyses of t ime from 
randomization to premature discontinuation from study and premature discontinuation from 
study drug by [CONTACT_25055].  
[IP_ADDRESS].  Participant Character istics  
Demographics, medical history, and concomitant illness will be summarized by [CONTACT_598012].  
[IP_ADDRESS].  Concomitant Therapy  
Concomitant medications, including previous therapy for diabetes, will be summarized by [CONTACT_598013]. In particular, the incidence of rescue therapy for 
severe, persistent  hyperglycemia will be analyzed as an exploratory safety endpoint.  
[IP_ADDRESS].  Treatment  Compliance  
Treatment compliance for each 4- to 6-week  interval is defined as taking at least 75% of the 
required  SC doses of study drug . Frequency counts and percentages of participants  compliant to 
study drug will be summarized by  [CONTACT_15057].  
9.4.3.  Efficacy Analyses  
[IP_ADDRESS].  Primary Analyses  
The primary efficacy analyses will be conducted to establish  superiority of LY3437943  0.[ADDRESS_790877]. An unstructured 
variance -covariance matrix will be used to model the within -participant  effects. Additional 
covariates may be added , and this MMRM analysis will be detailed in the SAP.  
[IP_ADDRESS].  Secondary Analyses  
In addition to the primary efficacy analysis of change in HbA1c in study population , the 
following secondary  study objectives  will be analyzed on the EAS : 
 change in HbA1c from baseline to  24 and 36  weeks  
 percentage of participants reaching HbA1c of <7.0% at 24 and/or 36 weeks  
 change in FBG from baseline to 24 and 36 weeks , and  
 change in body weight (kg) from baseline to 24 and 36 weeks . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 68 Continuous endpoints, including change in HbA1c from baseline to 24 and 36  weeks, c hange in 
FBG from baseline to  24 and 36 weeks , change in body weight (kg) from baseline to  24 and 36 
weeks , will be conducted in a manner similar to the primary efficacy analyses discussed in 
Section [IP_ADDRESS] . The details will be provided in SAP.  
[IP_ADDRESS].  Tertiary/Exploratory Analyses  
A Bayesian approach will be used as the dose –response model for change in HbA1c and body 
weight from baseline to the 24 -week endpoint. The placebo group will be modeled with 
LY3437943 doses. Details of the prior distribution specifications along with other analyses with 
regards to the exploratory objectives will be provided in the SAP.  
9.4.4.  Safety Analyses  
Unless specified otherwise, safety assessments will be guide d by [CONTACT_170255]3437943 doses with placebo irrespective of adherence to study drug or initiation of rescue 
therapy. Thus, safety analyses will be conducted using the FAS. Selected safety analyses may be 
conducted after excluding data  on rescue therapy or data after starting another antihyperglycemic 
medication.  
Adverse events will be coded from the actual term using the Medical Dictionary for Regulatory 
Activities (MedDRA) and reported with preferred terms and system organ class. Sel ected notable 
AEs of interest may be reported using high -level terms or Standardized MedDRA Queries. 
Summary statistics will be provided for incidence of TEAEs, SAEs, study discontinuation due to 
AEs, study drug discontinuation due to AEs, deaths, and othe r CV endpoints. Counts and 
proportions of participants experiencing AEs will be reported for each treatment group, and 
Fisher’s exact test will be used to compare the treatment groups.  
[IP_ADDRESS].  Hypoglycemia Events  
Hypoglycemic events will be analyzed. Incidence and  rate of hypoglycemia will be reported.  
Some analyses may be conducted excluding data after introducing another antihyperglycemic 
therapy.  
[IP_ADDRESS].  Gastrointestinal Events  
Summaries and analyses for incidence and severity of nausea, vomiting, and diarrhea will be 
provided by [CONTACT_91014].  
[IP_ADDRESS].  Central Laboratory Measures, Vital Signs, and Electrocardiograms  
Values and change from baseline to postbaseline values of central laboratory measures, vital 
signs, and selected ECG parameters will be summarized at each scheduled  visit. The analysis 
model to make comparisons among treatment groups relative to continuous change from baseline 
values assessed over time will be an MMRM similar to the primary efficacy analysis and with 
baseline measurement as a covariate. An unstructur ed covariance structure will model 
relationship of within -participant errors.  
The percentages of participants with treatment -emergent (TE) abnormal, high, or low measures 
(including laboratory, vital, and ECG parameters) will be summarized and compared be tween 
treatment groups using Fisher’s exact test.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 69 The analysis details will be provided in the SAP.  
9.4.5.  Pharmacokinetic/Pharmac odynamic Analyses  
LY3437943 concentration data will be summarized and analyzed using a population PK 
approach via nonlinear mixed -effects modeling. The relationships between LY3437943 dose 
and/or concentration and selected efficacy, tolerability, and safety endpoints may be 
characterized. Additionally, the impact of intrinsic and extrinsic factors , such as age, weight, 
gender, and rena l function on PK and/or PD parameters , may be examined as needed. If antidrug 
antibody titers are detected from immunogenicity testing, then the impact of immunogenicity 
titers on LY3437943 PK or any relevant PD parameters may also be examined.  Additional 
analyses may be conducted if they are deemed appropriate. Further details on PK and PK/PD 
analyses will be provided in the PK/PD analysis plan.  
9.4.6.  Evaluation of Immunogenicity  
The frequency and percentage of participants  with preexisting ADA and with treatme nt-
emergent  ADA+ to LY3437943  may be tabulated. Treatment -emergent ADAs are defined as 
those with a titer 2 -fold (1 dilution) greater than the minimum required dilution if no ADAs were 
detected at baseline (treatment -induced ADA) or those with a 4 -fold (2 dilutions) increase in titer 
compared to baseline if ADAs were detected at baseline (treatment -boosted ADA). For the 
treatment -emergent  ADA+ participants , the distribution of maximum titers may be described. 
The frequency of neutralizing antibodies  against  LY3437943 , if performed, may be tabulated in 
treatment -emergent  ADA+ participants . If cross -reactivity to native GIP , GLP -1, and glucagon  
or neutralizing antibodies against native GIP , GLP -1, and glucagon  assays are performed, the 
frequency of each may be reported.  
The relationship between the presence of antibodies and the PK parameters and PD response 
including safety and efficacy to LY3437943  may be assessed.  
9.4.7.  Subgroup Analyses  
Subgroup analyses of important factors, including baseline BMI, baseline HbA1c , and other 
factors to be specified in the SAP , are planned for the key outcomes. The models used for these 
analyses will vary depending on the subgroups and the outcome. More details of the modeling 
will be provided in the SAP. Other exploratory subg roup analyses may be performed as deemed 
appropriate.  
9.5. Interim Analyses  
An interim efficacy and safety assessment after all participants complete Visit 9 (Week 16) of 
the treatment period will be conducted to provide initial guidance for the design of futu re clinical 
studies of LY3437943. An internal AC will be formed to review the interim analyses for the 
safety and efficacy reports in an unblinded manner. Additional interim analyses may be 
conducted to monitor safety of study participants . Details on the timing of the interim analyses , 
operational support , and unblinding will be specified in the AC charter  and in the study 
unblinding plan.  Study team  members who have potential contact [CONTACT_598014].  Information tha t may unblind the study during the analyses will 
not be reported to study sites or  blinded study team members before the study has been 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790878] completed 36 weeks of treatment and the 4 -
week follow -up period. Participants and investigators will remain blinded until the completion of 
the study.  
The cancellation or addition of an interim analysis c an be determined at any time during the 
study and will not require a protocol amendment.  
9.6. Data Monitoring Committee (DMC)  
Not applicable.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 71 10. Supporting Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerat ions 
10.1.1.  Regulatory and Ethical Considerations  
● This study will be conducted in accordance with the protocol and with the 
following:  
○ consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for Int ernational Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines  
○ applicable ICH Good Clinical Practice (GCP) Guidelines , and  
○ applicable laws and regulations . 
● The protocol, protocol amendments, ICF, Investigator Brochure, and othe r 
relevant documents (for example, advertisements) must be submitted to an 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC)  by [CONTACT_52009]/IEC before the study is 
initiated.  
● Any amendments to  the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
 Protocols and any substantial amendments to the protocol will requir e health authority 
approval prior to initiation except for changes necessary to eliminate an immediate 
hazard to study participants.   
● The investigator will be responsible for the following:  
○ providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC  
○ notifying the IRB/IEC of SAEs or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures , and  
○ providing oversight o f study conduct for participants under their responsibility 
and adherence to requirements of 21  Code of Federal Regulations (CFR), ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable loca l regulations . 
● Investigator sites are compensated for participation in the study as detailed in the 
Clinical Trial Agreement  (CTA) . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 72 10.1.2.  Informed Consent Process  
● The investigator or his  or her representative will explain the nature of the study, 
including the risks and benefits, to the participant or his  or her legally authorized 
representative and answer all questions regarding the study.  
● Participants must be informed that their participation is voluntary. Participants or 
their legally authorized represe ntative  will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_790879] (HIPAA) 
requirements, where applicable, and the IRB/IEC or stu dy center.  
● The medical record must include a statement that written informed consent was 
obtained before the participant was entered in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
● Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
● A copy of the ICF(s) must be provided to the participant or the participant’s 
legally authorized representative and is kept on file.  
 Participants who are rescreened are required to sign a new ICF.  
10.1.3.  Data Protection  
● Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records, datasets , or tissue samples that are transferred to the sponsor will  contain 
the identifier only; participant names or any information which would make the 
participant identifiable will not be transferred.  
● The participant must be informed that his  or her personal study -related data will 
be used by [CONTACT_598015]. The level of 
disclosure must also be explained to the participant who will be required to give 
consent for his  or her data to be used as described in the informed consent.  
● The participant must be informed that his  or her medical records may be 
examined by [CONTACT_454589], by [CONTACT_6667]/IEC members, and by [CONTACT_57764].  
● The sponsor has processes in place to ensure data protection, information security , 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event of a data security breach . 
10.1.4.  Committees Structure  
An independent CEC  will be formed to adjudic ate major adverse cardiovascular events , deaths , 
and pancreati tis AEs. Sections  [IP_ADDRESS]  and [IP_ADDRESS]  outline additional information on  pancreatic 
and cardiovascular adjudication committees , respectively . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 73 An internal AC will be formed compromising individuals with expertise  needed for the 
evaluation and interpretation of the results from the interim analyses. The AC for this study is 
comprise d of 3 members: one clinical physician, one GPS physician, and one  statistician , 
including a designated chairperson . The AC will include members from Lilly  only.  
The primary responsibility  of the AC is  to review the efficacy and safety reports after all 
participants reach 16 weeks of treatment in an unblinded manner.  The details regarding number 
of participants and analysis plan will be provided in the AC charter (see Section 9.5).  
10.1.5.  Dissemination of Clinical Study Data  
Required clinical trial registries (for exam ple, ClinicalTrials.gov) will be updated with the results 
from registered clinical trials regardless of the research outcome in accordance with local laws 
and regulations.  
All CSRs, amendments , and addenda will be submitted to external regulatory authorit ies, 
external partners (as applicable) , and sites.  
10.1.6.  Data Quality Assurance  
● All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically (for example, 
laboratory data ). The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189].  
● The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF.  
● The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct access to source data 
documents.  
● Monitoring details describing strategy (for example, risk -based initiatives in 
operations and quality , such as risk management and mitigation strategies and 
analytical risk -based monitoring), methods, responsibilities , and requirements, 
including handling of noncompliance issues and monitoring techniques , are 
provided in the Monitori ng Plan.  
● The sponsor or designee is responsible for the data management of this study , 
including quality checking of the data.  
● The sponsor assumes accountability for actions delegated to other individuals (for 
example, contract research organizations).  
● Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are 
being protec ted; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 74 ● Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_170279] (CTA) unless local regulations or institutional policies 
require a longer retention period. No records may be destroyed during the 
retention period  without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor.  
● In addition, Sponsor or its representatives will periodically check a sample of the 
participant data rec orded against source documents at the study site. The study may be 
audited by [CONTACT_226422], and/or regulatory agencies at any time. 
Investigators will be given notice before an audit occur s. 
Data Capture System  
The investigator is respons ible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor .  
An electronic data capture system (EDC) will be used in this study for the collection of CRF 
data. The investigator maintains a separate source for the data entered by [CONTACT_82413] -provided EDC system. The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by s igning the CRF . 
Additionally, clinical outcome assessment data ( participant/clinician -focused outcome 
instrument ) will be collected by [CONTACT_2299]/authorized study personnel , via a paper source 
document and will be transcribed by [CONTACT_598016] . 
Data collected via the sponsor -provided data capture system  will be  stored at third -party . The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system . Prior t o decommissioning, the investigator will receive an archival 
copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system and reports  will be pro vided to the investigator for review 
and retention. Data will subsequently be transferred from the central vendor to the Sponsor data 
warehouse.  
Data from complaint forms submitted to Sponsor will be encoded and stored in the global PC 
management system.  
10.1.7.  Source Documents  
● Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
● Data reported on the CRF or entered in the eCRF that are  transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medical records  must be 
available.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 75 ● Definition of what constitutes source data can be found in study training material .  
10.1.8.  Study and Site Start and Closure  
[IP_ADDRESS].  Discontinuation of the Study  
The sponsor designee reserves the right to terminate the study at any time for any reason at the 
sole discretion of the sponsor. The study will be discontinued if Lilly or its designee  judges it 
necessary for medical, safety, regulatory, or other reasons consistent with applicable laws, 
regulations , and GCP.  
Medical Oversight and Safety Review  
Ongoing safety review(s) by [CONTACT_598017]. Such 
reviews will include  
 monitoring and assessing the safety information collected during the trial both in real 
time and periodically  
 reviewing safety data for trends that need action , and  
 detecting adverse drug/device effects.  
A safety investigation will be triggered to determine if the study should be terminated early 
based on the following criteria:  
 Two study partici pants develop the same TEAE or SAE considered possibly or 
probably related to study drug that is s evere or medically significant but not immediately 
life-threatening; or where hospi[INVESTIGATOR_39676]; 
or is disabling ; or limits self -care activities of daily living.  
 One study participant develops any TEAE or SAE regardless of attribution to 
study drug that has l ife-threatening consequences or requires urgent intervention .  
 Death of any study participant at any time . 
 Any other clinically significant safety signal . 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study  of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the participant and assures 
appropriate participant therapy and/or follow -up. 
[IP_ADDRESS].  Discontinuation of Study Sites  
The sp onsor designee reserves the right to close the study site at any time for any reason at the 
sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is 
considered closed when all required documents and study supplies h ave been collected and a 
study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 76 Reasons for the ea rly closure of a study site by [CONTACT_11004]  
● failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor ’s procedures, or GCP guideline s 
● inadequate recruitment of participants by [CONTACT_093] , and  
● discontinuation of further study intervention development . 
10.1.9.  Publication Policy  
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publica tion by a peer -reviewed journal . 
10.1.10.  Investigator Information  
Physicians with experience in Phase II or Phase III diabetes clinical trials will participate as 
investigators in this clinical trial.   
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 77 10.2. Appendix 2: Clinical Laboratory Tests  
● The tests detailed below will be performed  by [CONTACT_2237] . 
● Local laboratory results are only required in the event that the central laboratory 
results are not available in time for either study intervention administration and/or 
response evaluation. If a local s ample is required, it is important that the sample 
for central analysis is obtained at the same time. In circumstances where the 
sponsor approves local laboratory testing in lieu of central laboratory testing (in 
the table below), the local laboratory must  be qualified in accordance with 
applicable local regulations.  
● Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
● Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
● Pregnancy testing (please r efer to Section  5.1 (Inclusion Criteria ) for screening 
pregnancy criteria ). 
Investigators must document their review of the laboratory safety results.   
Laboratory results  that could unblind the study will not be reported to investigative sites or other 
blinded personnel  and are denoted in the table below .  
 
Clinical Laboratory Tests   Comments  
Hematology  Assayed by [CONTACT_11007] -designated laboratory  
Hemoglobin   
Hematocrit   
Erythrocyte count (RBCs - red blood cells)  
Mean cell volume   
Mean cell hemoglobin   
Mean cell hemoglobin concentration   
Leukocytes (WBCs - white blood cells)   
Differential   
   Neutrophils, segmented   
   Lymphocytes   
   Monocytes   
   Eosinophils   
   Basophils   
Platelets   
Cell morphology (RBCs and WBCs)   
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790880] bilirubin   
Alkaline phosphatase (ALP)   
Alanine aminotransferase (ALT)   
Aspartate aminotransferase (AST)   
Gamma -glutamyl transferase (GGT)   
Blood urea nitrogen (BUN)   
Creatinine   
Creatine kinase (CK)   
Total protein   
Albumin   
Calcium   
Phosphorus   
Glucose   
Lipid Panel  Assayed by [CONTACT_11007] -designated laboratory  
High -density lipoprotein cholesterol (HDL -C)  
Low-density lipoprotein cholesterol (LDL -C)  
Very low-density lipoprotein cholesterol 
(VLDL -C)  
Total cholesterol   
Triglycerides   
Urinalysis  Assayed by [CONTACT_11007] -designated laboratory  
Specific gravity   
pH  
Protein   
Glucose   
Ketones   
Bilirubin   
Urobilinogen   
Blood   
Nitrite   
Urine leukocyte esterase   
Microscopic examination of sediment   
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 79 Hormones (female)   
Serum pregnancy  Assayed by [CONTACT_11007] -designated laboratory  
Urine pregnancy  Evaluated locally  
Follicle stimulating hormone (FSH)  Assayed by [CONTACT_11007] -designated laboratory  
Urine Chemistry  Assayed by [CONTACT_11007] -designated laboratory  
Albumin   
Creatinine   
Calculations  Generated by [CONTACT_11007] -designated 
laboratory  
eGFR (CKD -EPI)   
Urinary albumin/creatinine ratio (UACR)   
Pharmacokinetic Samples – LY3437943 
concentration  Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites.  
Biomarkers  Assayed by [CONTACT_11007] -designated laboratory  
HbA1c   
Calcitonin   
Pancreatic amylase   
Lipase   
Insulin   
Glucagon   
C-peptide   
Intact proinsulin   
Longitudinal biomarkers  Assayed by [CONTACT_11007] -designated laboratory. 
Results in this group of biomarkers ( see 
Section 10.11 ), which are not defined in 
this table , will not be provided to the 
sites.  
Endpoint biomarkers  Assayed by [CONTACT_11007] -designated laboratory. 
Results in this group of biomarkers ( see 
Section 10.11 ), which are not defined in 
this table , will not be provided to the 
sites.  
Genetic sample  Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites.  
Exploratory samples  Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites.  
Exploratory storage samples:   
   Serum   
   Plasma (EDTA)   
   P800   
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 80    Whole blood (EDTA)   
Immunogenicity Samples  Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites.  
   Anti-LY3437943 antibodies   
   Anti-LY3437943 antibodies neutralization   
Hypersensitivity Tests   Laboratory assessments 
should be performed if the 
participant experiences 
generalized urticaria or if 
anaphylaxis is suspected.  
 Collect sample after the participant 
has been stabilized, and within 1 to 2 
hours of the event; however, 
samples may be obtained as late as  
[ADDRESS_790881] the time at 
which the sample was collected.  
 Obtain a follow -up sample at 
the next regularly scheduled 
visit or after 4  weeks, 
whichever is later . 
 
  Anti-LY antibodies ( immunogenicity/ADA)  Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites . 
   LY3437943 concentrations (PK)  Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites.  
Approved on 29 Aug 2022 GMT
CCI
CCI
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790882] Will be perform ed if a validated assay 
is available.  
Assayed by [CONTACT_11007] -designated 
laboratory. Results will not be 
provided to the investigative sites.  
Note:  The basophil activation test is an 
in vitro cell -based assay that only 
requires a serum sample. It is a surrogate 
assay for drug -specific IgE, but is not 
specific for IgE.  
   Complement (C3, C3a , and C5a)  Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites . 
   Cytokine panel (IL‐6, IL‐1β, and IL‐10)  Assayed by [CONTACT_11007] -design ated laboratory. 
Results will not be provided to the 
investigative sites.  
 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 82 10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -Up, and Reporting  
 The definitions and procedures detailed in this appendix are in accordance with 
International Organization for Standardization (ISO) [ZIP_CODE].  
 Both the investigator and the sponsor will comply with all local medical device reporting 
requirements.  
 The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study.  
10.3.1.  Definition of AE  
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with t he use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product . 
 An AE that can be attributed to a medical device or device constituent deficiency is 
referred to as ADE ( adverse device effect ). It is any u ntoward medical occur rence, 
unintended disease or injury, or untoward clinical signs (including abnormal laboratory 
finding) in study participants, users, or other persons, whether or not related to the 
investigational medical device. This definition inclu des events related to  the 
investigational medical device or comparator and events related to the procedures 
involved except for events in users or other persons, which only include events related 
to investigational devices.  
 
Events Meeting  the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( for example,  ECG, radiological scans, and vital sign 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator ( that is,  not related 
to progression of underlying disease).  
 Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after study intervention administration even 
though they may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug –drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 83 AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.   
 “Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfill the definition of an AE or SAE .  
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
 The disease  or disorder being studied or expected progression, signs, or sympto ms of 
the disease  or disorder being studied, unless more severe than expected for the 
participant’s condition.  
 Medical or surgical procedure ( for example,  endoscopy and appendectomy): the 
condition that leads to the procedure is the AE.  
 Situations in which  an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.   
10.3.2.  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( for example,  hospi[INVESTIGATOR_597969], death due 
to progression of disease).  An SAE that can be attri buted to a medical device or device 
constituent is referred to as SADE (serious adverse device effect). An SAE that can be attributed 
to a not previously identified device risk is referred to as UADE (unanticipated adverse device 
effect) . 
SAE is defined as  any untoward medical occurrence that, at any dose:  
  Results in death  
  Is life -threatening  
The term “life-threatening ” in the definition of “serious ” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
  Requires inpatient hospi[INVESTIGATOR_63995] g hospi[INVESTIGATOR_059]  
 In general, hospi[INVESTIGATOR_597970]/or treatment that would not have been appropriate in the 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 84 physician’s office or outpatient setting. Complications that occur durin g hospi[INVESTIGATOR_10911]. If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary, the AE should be considered serious.  
 Hospi[INVESTIGATOR_5186] n for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.  
  Results in persistent disability  or incapacity  
 The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance , such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( for example,  sprained ankle) , which may interfere with  or 
prevent everyday life functions but do not constitute a substantial disruption . 
  Is a congenital anomaly  or birth defect  
  Other situations  
 Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other si tuations , such as important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_10913]. These events should usually be considered 
serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias , or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or 
drug abuse . 
10.3.3.  Definition of Product Complaints  
Product Complaint  
A PC is any written, electronic, or oral communication that alleges deficiencies related to the 
identity, quality, durability, reliability, safety, effectiveness , or performance of a study  
intervention . When the ability to use the study intervention safely is impacted, the following 
are also PCs:  
deficiencies in labeling information, and  
use errors for device or drug –device combination products due to ergonomic design elements 
of the product.  
Product complaints related to study interventions used in clinical trials are collected in order to 
ensure the safety of participants, monitor quality, and to facilitate process a nd product 
improvements.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790883] the site as soon as possible if he or she has a 
PC or problem with the study intervention  so that the situation can be assessed.  
 An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product Complaints  
 
 AE, SAE , and PC Recording  
 When an AE/SAE /PC occurs, it is the responsibility of the investigator to review all 
documentation ( for example , hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE /PC information in the 
participant’s medical records, in accordance with the in vestigator’s normal clinical 
practice . AE/SAE information is reported o n the appropriate  (e)CRF  page and P C 
information is reported on the PC Form.  
Note:  An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor or designee  in lieu of completion of the (e)CRF page  for AE/SAE 
and the PC Form for PCs . 
 There may be instances when copi[INVESTIGATOR_51958] . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_1309] t he medical records before 
submission to Sponsor or designee . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs  or symp toms) will be documented as the AE/SAE.   
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:   
 Mild:  A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living . 
 Moderate:  A type of adverse event that is usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the research 
partici pant. 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 86  Severe: A type of adverse event that interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention . 
An AE that is assessed as severe should not be confused with a SAE. Severe is a 
category utilized for rating the intensity of an event; and both AEs and SAEs can be 
assessed as severe.  
An event is defined as “serious ” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  
 A “reas onable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
 The investigator will use clinical judgment to determine the relationship.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult t he IB and/or Product Information, for marketed 
products,  for marketed products, in his  or her assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he  or she 
has reviewed the AE/SAE and has provided an assessment of causalit y. 
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to Sponsor or designee . However, it 
is very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to Sponsor or designee . 
 The investigator may change his  or her opi[INVESTIGATOR_9242] -up 
information and send a SAE follow -up report with the updated causality assessment.  
 The causal ity assessment is one of the criteria used when determining regulatory 
reporting requirements.   
 
Follow -Up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_52017]/or causality of the AE or SAE as fully as possible . 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 87  If a participant dies during participation in the study or during a recognized follow -up 
period, the inv estigator will provide Sponsor or designee with a copy of any 
post-mortem findings , including histopathology.   
 
10.3.5.  Reporting of SAEs  
SAE Reporting via an Electronic Data Collection Tool  
 The primary mechanism for reporting an SAE will be the electronic data collection 
tool. 
 If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.   
 The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
 After the study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new SAE from a study participant or r eceives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see next 
section) or to the sponsor contact [CONTACT_598018].  
 Contacts for SAE reporting can be found in study training material.   
 
SAE Reporting via Paper CRF  
Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the spon sor contacts for SAE reporting . 
Initial notification via telephone does not replace the need for the investigator to complete and 
sign the SAE CRF pages within the designated reporting time frames.  
Contacts for SAE reporting can be found in study training material .  
10.3.6.  Regulatory Reporting Require ments  
SAE Regulatory Reporting  
 Prompt notification by [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities towards the safety of 
participants and the safety of a study intervention under clinical investigation 
are met.  
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific  
regulatory requirements relating to safety reporting to the regulatory authority, 
IRB/IEC , and investigators.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 88 ● An investigator who receives an investigator safety report describing a SAE or 
other specific safety information ( for example,  summary or listi ng of SAEs) 
from the sponsor will review and then file it along with the IB and will notify 
the IRB/IEC, if appropriate according to local requirements.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 89 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
Women of childbearing potential (WOCBP) and  women not of childbearing potential 
(WNOCBP)  may participate in this trial. WOCBP need to either remain abstinent (if this is their 
usual preferred lifestyle) or if they are in a same -sex relationship exclusively, they do not need to 
use contraception. If they are in a heterosexual relationship, they need to use contraception as 
described below throughout the study and for [ADDRESS_790884]/Phrase  Definiti on 
Women of 
childbearing 
potential  Females are considered a WOCBP if  
 they have had at least one cycle of menses, or  
 they have Tanner [ADDRESS_790885] development.  
 
Any amount of spotting should be considered menarche.  
Women not of 
childbearing 
potential  Females  are considered WNOCBP if  
 they have a congenital anomaly such as Mullerian agenesis  
 they are infertile due to surgical sterilization, or  
 they are post -menopausal.  
 
Examples of surgical sterilization include hysterectomy, bilateral oophorectomy, 
and tubal ligation.  
Post-menopausal 
state The post -menopausal state should be defined as  
1. A woman at any age at least [ADDRESS_790886] -surgical bilateral oophorectomy 
with or without hysterectomy, confirmed by [CONTACT_31083]; or  
2. A woman at least [ADDRESS_790887] 
uterus, not on hormone therapy*, who has had cessation of menses for at 
least 12 consecutive months without an alternative medical cause, AND  
With a follicle -stimulating hormone >40 mI U/mL; or  
3. A woman [ADDRESS_790888] 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy . 
*Women should not be taking med ications during amenorrhea , such as oral 
contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators, or chemotherapy that could induce 
transient amenorrhea.  
Reproductive 
toxicology 
studies  Embryo -fetal studies are toxicity studies in pregnant animals designed to identify 
abnormalities in the development of fetuses, which could indicate potential for 
teratogenicity in humans. The relevant dosing period is during organogenesis.  
 
Please see guidance for s pecific participant populations below:  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 90  WOCBP who are completely abstinent as their preferred and usual lifestyle, or in a same -sex 
relationship, as part of their preferred and usual lifestyle  
Must…  Must not…  
agree to either remain abstinent, or   use periodic abstinence methods  
calendar  
ovulation  
symptothermal, or  
post-ovulation  
 declare abstinence just for the duration of 
a trial, or  
stay in a same -sex relationship without sexual 
relationships with males   use the withdrawal method  
 
 
WOCBP who  are NOT completely abstinent as their preferred and usual lifestyle, or in a same -sex 
relationship, as part of their preferred and usual lifestyle : 
Topic  Condition  
Pregnancy testing  Negative serum  result at screening followed by a 
negative urine  result within [ADDRESS_790889] be highly effective 
(less than 1% failure rate) . 
 
Examples of different forms of contraception:  
Methods  Exam ples 
Highly effective contraception   combination oral contraceptive pi[INVESTIGATOR_31076]-pi[INVESTIGATOR_4382] 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198 
pounds or 90 kg)  
 total abstinence  
 vasectomy (if only sexual partner)  
 fallopi[INVESTIGATOR_31077] (if confirmed by 
[CONTACT_31084][INVESTIGATOR_8913])  
 combined contraceptive vaginal ring, or  
 intrauterine devices . 
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical 
sponges  
 barrier method with use of a  spermicide  
o condom with spermicide  
o  diaphragm with spermicide, or  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 91 o female condom with spermicide . 
Note:  The barrier method must include use of a 
spermicide ( that is , condom with spermicide, 
diaphragm with spermicide, and female condom 
with spermicide) to be  considered effective.  
Ineffective forms of contraception   spermicide alone  
 immunocontraceptives  
 periodic abstinence  
 fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, and 
symptothermal)  
 withdrawal  
 post coita l douche , and  
 lactational amenorrhea . 
 
 Males  
Topic  Guidance  
For all men    should refrain from sperm donation for 
the duration of the study and for 5 
terminal half -lives of the study drug (30 
days)  plus [ADDRESS_790890] injection . 
Contraception for men with partners of 
childbearing potential   either remain abstinent (if this is their 
preferred and usual lifestyle), or  
 must use condoms  plus 1 additional 
highly effective (less than 1% failure rate) 
method of contraception  for the duration 
of the study, and for 5 terminal half -lives 
of the study drug (30 days) plus [ADDRESS_790891] 
injection . 
Contraception for men in exclusively same -sex 
relationships, as their preferred and usual lifestyle  Are not required to use contraception . 
 
 Examples of highly effective, effective , and unacceptable methods of contraception can be found 
below.  
Methods  Examples  
Highly effective contraception   combination oral contraceptive pi[INVESTIGATOR_31076]-pi[INVESTIGATOR_4382] 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198 
pounds or 90 kg)  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 92  total abstinence  
 vasectomy (if only sexual partner)  
 fallopi[INVESTIGATOR_31077] (if confirmed by 
[CONTACT_31084][INVESTIGATOR_8913])  
 combined contraceptive vaginal ring, or  
 intrau terine devices . 
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical 
sponges , or 
 barrier method with use of a spermicide  
o condom with spermicide  
o  diaphragm with spermicide, or  
o female condom with spermicide . 
Note:  The barrier method must include use of a 
spermicide ( that is , condom with spermicide, 
diaphragm with spermicide, and female condom 
with spermicide) to be considered effective.  
Ineffective forms of contraception   spermicide alone  
 immunocontraceptives  
 periodic abstinence  
 fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, and 
symptothermal)  
 withdrawal  
 post coital douche , and  
 lactational amenorrhea . 
 
Collection of Pregnancy Information  
Male participants with partners who become pregnant  
● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this study. This applies only to male partici pants who receive  study 
intervention . 
● After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on the 
appropriate form and submit it to the sponsor within 24 hours  of learning of the 
partner’s pregnancy. The female partner will also be followed to determine the 
outcome of the pregnancy. Information on the status of the mother and child will 
be forwarded to the sponsor. Generally, the follow -up will be no longer than  6 to 
8 weeks following the estimated delivery date. Any termination of the pregnancy 
will be reported regardless of fetal status (presence or absence of anomalies) or 
indication for the procedure.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 93 Female participants who become pregnant  
● The investigato r will collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial information 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours  of learning of a participan t’s pregnancy.  
● The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate , 
and the information will be forwarded to the sponsor. Generally, follow -up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. 
Any termination of pregnancy will be reported, regardless of fetal status (presence 
or absence  of anomalies) or indication for the procedure.  
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion  (occurring at <20 weeks gestational age) or still birth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be reported as such.  
● Any post -study pregnancy -related SAE considered reasonably related to the study 
interventio n by [CONTACT_170272]  8.3.1 . While the investigator is not obligated to actively see k this 
information in former study participants, he or she may learn of an SAE through 
spontaneous reporting . 
● Any female participant who becomes pregnant while participating in the study 
will discontinue study drug. If the participant is discontinued fro m the study drug, 
follow the standard discontinuation process for each study period.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 94 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow -Up 
Assessments  
For testing selected, analysis is required to be completed by [CONTACT_11008] -designated central 
laborato ry, except for microbiology.  
Local testing may be performed in addition to central testing  when required for immediate 
participant management.  
Results will be reported if a validated test or calculation is available.  
 
Hematology  Clinical Chemistry  
Hemoglobin  Total bilirubin  
Hematocrit  Direct bilirubin  
Erythrocytes (RBCs - red blood cells)  Alkaline phosphatase (ALP)  
Leukocytes (WBCs - white blood cells)  Alanine aminotransferase (ALT)  
Differential:  Aspartate aminotransferase (AST)  
    Neutrophils , segmented  Gamma -glutamyl transferase (GGT)  
    Lymphocytes  Creatine kinase (CK)  
    Monocytes  Other Chemistry  
    Basophils  Acetaminophen  
    Eosinophils  Acetaminophen protein adducts  
Platelets  Alkaline phosphatase isoenzymes  
Cell morphology (RBC and WBC)  Ceruloplasmin  
Coagulation  Copper  
Ethyl alcohol (EtOH)  
Prothrombin time, INR (PT -INR)  Haptoglobin  
Serology  Immunoglobulin IgA (quantitative)  
 Hepatitis A virus (HAV) testing:  Immunoglobulin IgG (quantitative)  
    HAV total antibody  Immunoglobulin IgM (quantitative)  
    HAV IgM antibody  Phosphatidylethanol (PEth)  
Hepatis B virus (HBV) testing:  Urine Chemistry  
    Hepatitis B surface antigen (HBsAg)  Drug screen  
    Hepatitis B surface antibody (anti -HBs)  Ethyl glucuronide (EtG)  
    Hepatitis B core total antibody (anti -HBc)  Other Serology  
    Hepatitis B core IgM antibody  Anti-nuclear antibody (ANA)  
    Hepatitis B core IgG antibody  Anti-smooth muscle antibody (ASMA) a 
    HBV DNA  d Anti-actin antibody b 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 95 Hepatis C virus (HCV)  testing:  Epstein -Barr virus (EBV) testing:  
    HCV antibody      EBV antibody  
    HCV RNA  d     EBV DNA  d 
Hepatitis D virus (HDV) testing:  Cytomegalovirus (CMV) testing:  
    HDV antibody      CMV antibody  
Hepatitis E virus (HEV) testing:      CMV DNA  d 
    HEV IgG antibody  Herpes simplex virus (HSV) testing:  
    HEV IgM antibody      HSV (Type 1 and 2) antibody  
    HEV RNA d     HSV (Type 1 and 2) DNA  d 
Microbiology c Liver kidney microsomal type 1 (LKM -1) antibody  
Culture:   
    Blood   
    Urine   
Abbreviations:  Ig = immunoglobulin;  INR = international normalized ratio ; PT-INR=prothrombin time -international 
normalized ratio   
 
a Not required if anti -actin antibody is tested.  
b Not required if anti -smooth muscle antibody (ASMA) is tested.  
c Assayed ONLY by [CONTACT_1697] -designated local laboratory; no central testing available.  
d Reflex/confirmation dependent on regulatory requirements, testing availability, or both.
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 96 10.6. Appendix 6: Genetics  
Use/Analysis of DNA  
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorpti on, distribution, metabolism, and excretion; mechanism of action of the 
drug; disease etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, a  blood sample will be 
collected for DNA analysis f rom consenting participants.  
● DNA samples may be used for research related to LY3437943  or diabetes 
mellitus and related clinical traits or complications, including nonalcoholic 
steatohepatitis or obesity and related diseases. They may also be used to develop 
tests or assays , including diagnostic tests related to LY3437943, study 
interventions related to this drug class,  or diabetes mellitus and related clinical 
traits or complications, including nonalcoholic steatohepatitis or obesity . Genetic 
research  may consist of the analysis of one or more candidate genes, the analysis 
of genetic markers throughout the genome,  or analysis of the entire genome .  
● The samples may be analyzed as part of a multi -study assessment of genetic 
factors involved in the resp onse to  LY3437943 or study interventions related to 
this class to understand study disease or related conditions.  
● The results of genetic analyses may be reported in the CSR or in a separate study 
summary.  
● The sponsor will store the DNA samples in a sec ure storage space with adequate 
measures to protect confidentiality.  
● The samples will be retained while research on  LY3437943  or diabetes mellitus 
and related clinical traits or complications, including nonalcoholic steatohepatitis 
or obesity  continues b ut no longer than  15 years or other period as per local 
requirements.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 97 10.7. Appendix 7: World Health Organization Classification of Diabetes 
and Diagnostic Criteria  
Type 1 Diabetes : Type 1 diabetes is judged to be present when the classical symptoms of 
diabetes (thirst, polyuria, wasting and stupor, or coma) are associated with readily detectable 
concentrations of glucose and ketone bodies in the blood and urine. Insulin treatment is 
necessary not only to control hyperglycemia but also to prevent spontan eous ketosis and death.  
Type 2 Diabetes : Type 2 diabetes, although often asymptomatic, may also present with classical 
hyperglycemic symptoms (thirst, polyuria, and weight loss), but despi[INVESTIGATOR_597971]. Coma is rare in 
type 2 diabetes but may result from extreme hyperglycemia and hyperosmolarity; lactic acidosis 
or ketoacidosis can also occur in fulminating illness (for example, severe infection or mesenteric 
artery thrombosi s) due to an acute increase in insulin requirements, but spontaneous ketosis does 
not occur. Some patients with type 2 diabetes later progress to a state of absolute insulin 
deficiency (Alberti and Zimmet 1998).  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 98 10.8. Appendix 8: [LOCATION_001] Heart Association Functional Classification 
IV CHF  
 
[LOCATION_001] Heart Association (NYHA) classification NYHA grading MET*  
Class I  No limitations. Ordinary physical activity does not cause undue fatigue, dyspnea , or 
palpi[INVESTIGATOR_814] (asymptomatic LV dysfunction). >7  
 
Class II  Slight limitation of physical activity. Ordinary physical activity results in fatigue, 
palpi[INVESTIGATOR_332], dyspnea , or angina pectoris (mild CHF). 5  
 
Class III  Marked limitation of physical activity. Less than ordinary physical activity leads to 
symptoms (moderate CHF). 2 –[ADDRESS_790892] (severe CHF). 1.6  
 
*MET (metabolic equivalent) is defined as the resting VO2 for a 40 -year-old, 70-kg man.  1 MET 
= 3.5  mL O2 /min/kg body wei ght.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 99 10.9. Appendix 9: Protocol GZBD Standardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, Vital Signs, 
ECG , SMBG  and MNSI  
The following information has been adapted from standardized physical measurement protocols 
for the World Health Organization’s STEPwise approach to Surveillance (STEPS) ( WHO 2017 ).  
Measuring Height  
Step 1.  Ask the participant to remove their footwear and  any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_291612]).  
Step 2.  Ask the participant to stand on the calibrated height measuring board (stadiometer ) or 
against a wall with their feet together and their knees straight with their heels against the 
backboard,  the stadiometer , or the wall . 
Step 3.  Ask the participant to look straight ahead without tilting their head up.  
Step 4.  Ask the participant to bre athe in and stand tall. Measure and record the participant’s 
height in centimeters  to [ADDRESS_790893].  
Measuring Weight  
 Body weight measurements should be done in a consistent manner using a calibrated 
electronic scale capable of measuring weight in kilog rams  to [ADDRESS_790894].  
 All weights for a given participant should be measured using the same scale, whenever 
possible, at approximately the same time in the morning after evacuation of bladder 
contents .  
 Body weight must be measured in fasting state. If the participant is not fasting, the 
participant should be called in for a new visit within the visit window to have the 
fasting body weight measured.  
Step 1 . Ask the participant to empty their pockets and remove their footwear, outerwear (coat, 
jacket, etc .), and any headgear (light headgear worn for religious reasons can remain, but this 
should be worn by [CONTACT_291613]).  
Step 2 . Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a slopi[INVESTIGATOR_126154], or a rough, uneven surface).  
Step [ADDRESS_790895] the skin without compressing the soft 
tissue.  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790896] 0 .5 cm. 
The measuring tape should be removed between t he 2 measurements. Both 
measurements will be recorded in the eCRF. If the difference between the 2 
measurements exceeds 1  cm, this set of measurements should be discarded and the 2 
measurements repeated.  
Step 1 : Ask the participant to wear little clothing (if available, patient gowns could also be used).  
Step 2 : Ask the participant to stand with their feet close together, arms at their side, body weight 
evenly distributed.  
Step 3 : Ask the participant to relax and measure the participant’s waist circumferenc e. 
Vital Sign Measurements  
 Vital sign measurements (blood pressure and HR, measured by [CONTACT_117682]) should 
be taken before obtaining an ECG tracing and before collection of blood 
samples for laboratory testing.  
 The participant should sit quietly for 5 minutes be fore vital sign 
measurements are taken.  
 For each parameter, 3 measurements will be taken using the same arm, 
preferably the nondominant arm.  
 The recordings should be taken at least 1 minute apart. Each measurement of 
sitting pulse and blood pressure needs to be recorded in the eCRF.   
 Blood pressure must be taken with an automated arm blood pressure 
equipment with full range of cuff sizes up to XL.  
 If blood pressure and pulse measurements are taken separately, pulse should 
be taken prior to blood pressure.  
Note : In the event pulse measurement cannot be taken via an automated blood pressure 
instrument, the preferred location for measurement of pulse is the radial artery.  
Orthostatic Vital Sig n Measurements  
 Orthostatic vital sign measurements (blood pressure and HR, measured by 
[CONTACT_117682]) should be taken before obtaining an ECG tracing and before collection 
of blood samples for laboratory testing. They should be done after completing 
the triplicate measures in the sitting position.  
 The participant should lie quiet ly for 5 minutes before vital sign 
measurements are taken.  
 The participant  should be comfortably lying flat without legs crossed, in a 
calm, quiet area for 5 minutes before vital sign measurements are taken.  
 For measurement of vital signs in the supi[INVESTIGATOR_112687], the arm should be 
supported by a pi[INVESTIGATOR_597972] 
(approximately halfway between the bed and the level of the sternum).  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790897] arm positioning results in erroneous BP values.  
o Upper arm below the level of the right atrium (for example, arm 
hanging down) results in readings that are too high.  
o Upper arm above the heart level results in readings that are too low.  
 Measure  BP and pulse rate once in the supi[INVESTIGATOR_2547].  
 After the BP and pulse rate are determined in t he supi[INVESTIGATOR_2547], the 
participant should immediately move to the standing position, bend the arm 
used for BP determination at the elbow , and rest the arm on an adjustable 
table or stand so that the upper arm is supported at the heart level.  
 Determine the  standing BP and pulse rate in the supported arm immediately 
after standing for 3 minutes. Only 1 measurement is needed.  
 Record all symptoms (AEs) that the participant  may experience , such as 
lightheadedness, syncope, or dizziness as AEs.  
Electrocardiogram  
 Electrocardiograms should be collected at least 30 minutes prior to collection of 
blood samples for laboratory testing, including PK samples . 
 Electrocardiogram s should be recorded after the participant has been supi[INVESTIGATOR_2525] 5 
minutes in a  quiet room.   
All d igital ECGs will be obtained using centrally provided ECG machines and will be 
electronically transmitted to a designated central ECG laboratory. The central ECG laboratory 
will perform a basic quality control check (for example, demographics and study det ails) and 
then store the ECGs in a database. In addition, tracings collected at the baseline, [ADDRESS_790898] at the central ECG laboratory for further evaluation of 
machine -read measurements or to meet regulatory requirements  at timepoints as per the SoA . 
The machine -read ECG intervals and HR may be used for data analysis and report -writing 
purposes, unless a cardiology  overreading of the ECGs is conducted prior to completion of the 
final study report (in which case, the overread data would be used).  
Self-Monitoring of Blood Glucose  
During the trial , participant s will monitor their blood glucose to assess efficacy of stu dy 
interventions,  using glucometers provided by [CONTACT_456]. Procedures described in this section 
will be initiated immediately after participant eligibility is confirmed at Visit 2.  
 
Glucose self -monitoring will consist of daily F BG measurements and QW 4-point BG 
measurements consisting of fasting  (before morning meal /after awakening ), before mid -day 
meal, dinner , and bedtime . In addition, a 7 -point daily glucose profile consisting of 
measurements obtained before each meal, approximately 2  hours after ea ch meal, and at bedtime 
per schedule provided in Section 1.3 (SoA). The complete [ADDRESS_790899] 
be collected on a subsequent day. At the weeks when 7 -point daily BG profile is taken, 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 102 participants will not be required to perform weekly 4 -point daily BG profiles. All self -monitori ng 
BG values will be recorded in participants’ diaries and will be discussed with the site personnel 
at each scheduled clinic visit. All events of hypoglycemia should also be recorded in the 
participant diary, according to instructions.  
 
The 7 -point self-monitoring of blood glucose  values and all hypoglycemic events should be 
entered into the eCRF.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c)  
 103  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c)  
 104 10.10.  Appendix 10: Patient -Reported Outcomes  
When feasible, the  self-administered questionnaires will be translated into the native language of 
the participant , linguistically validated and administered according to the SoA (Section 1.3). The 
language of the signed ICF will be considered the native language. If a translation is not 
available in the native language of a pa rticip ant at baseline, the questionnaire(s) will not be 
administered for that participant  for the duration of the trial. If PRO questionnaire (s) is not 
collected due to a translation not being available, this will not be considered a protocol deviation.  
When the PRO  questionnaire (s) is collected as per the SOA , the questionnaire (s) should be 
completed before the participant has discussed their medical condition or progress in the study 
with the investigator and/or site staff, if the participant is not adversel y affected by [CONTACT_598019].  
Short Form -36 version 2 Health Survey acute form, 1 -week recall version  
The SF -36v2 acute form, 1 -week recall version  is a 36 -item generic, 
participant -administered measure designed to assess the following 8 domains : 
o Physical Functioning  
o Role -Physical  
o Bodily Pain  
o General Health  
o Vitality  
o Social Functioning  
o Role -Emotional , and   
o Mental Health.  
The Physical Functioning domain assesses limitations due to health “now” while 
the remaining domains assess functioning “in the  past week.” Each domain is 
scored individually , and information from these 8 domains is further aggregated 
into 2 health component summary scores: Physical Component Summary and 
Mental Component Summary. Items are answered on Likert scales of varying 
lengths (3 -point, 5 -point, or 6 -point scales). Scoring of each domain and both 
summary scores are norm  based and presented in the form of T -scores, with a mean 
of 50 and SD of 10; higher scores indicate better levels of function and/or better 
health (Maruish 2 011).  
Eating Inventory  
The Eating Inventory  is a 51 -item, participant -administered measure designed to 
assess three aspects of eating behavior (Stunkard and Messick 1985)  
 dietary restraint (21 items)  
 disinhibition (16 items ), and  
 perceived hunger (14 it ems).  
Thirty -six items are rated in true/false format, 14 items are rated on a 4 -point scale, 
and 1 item is rated on a 6 -point scale. Dietary restraint refers to both cognitive and 
behavioral dietary restraint, disinhibition measures the tendency to overe at in 
response to external cues, and perceived hunger measures susceptibility to feelings 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 105 of hunger. Higher domain scores denote higher levels of restrained eating, 
disinhibited eating, and predisposition to hunger, respectively.  
 Appetite Visual Analog Scale  
The aim of the appetite Visual Analog Scale  (VAS) is to determine the effects of  
study treatments  on appetite sensation s and desire for specific foods.  
The questionnaires should be completed before the participant has discussed their 
medical condition or progress in the study with the investigator and/or site staff, if 
the participant is not adversely affected by [CONTACT_51993].  
 
The VAS scales will be analyzed as continuous variables on the 0 -100 scale for  
individual components. Over all appetite score is calculated as the average of the  4 
individual scores (satiety + fullness + [100 -prospective food consumption] +  [100-
hunger]/4 ) (van Can et al. 2014; Flint et al. 2000 ). The higher  overall appetite 
score indicates less appetite and th e lower score indicates more appetite . 
 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 106 10.11.  Appendix 11: Metabolic Mechanistic Biomarkers  
 
Mechanistic biomarkers will be measured at longitudinal intervals (longitudinal biomarkers) 
or less frequently to correspond with interim analysis, primary and second ary endpoints 
(endpoint biomarkers). Results will not be provided to the investigative sites.  To explore 
potential mechanisms of action related to changes in glucose, lipid, or nutrient metabolism, 
the following markers will be assessed:  
 Biomarkers related to  insulin sensitivity: fasting insulin, fasting C -peptide, 
homeostasis model assessment of insulin resistance ( [HOMA2 -IR] computed with 
fasting glucose and fasting insulin or fasting C -peptide), insulin -like growth factor 
binding protein 2 ( IGFBP -2), total adiponectin,  
 and leptin  
 Biomarkers related to  pancreatic beta or alpha cell function: homeostasis model 
assessment of beta -cell function ( [HOMA2 -B] computed with fasting glucose  and 
fasting insulin or fasting C -peptide), intact proinsulin, intact proinsulin/C -peptide 
ratio,  intact proinsulin/insulin ratio, and fasting  glucagon  
  
 Biomarker of fatty acid oxidation: beta -hydroxybutyrate  
 Bioma rkers of lipolysis: free fatty acids and glycerol  
 Biomarker of purine metabolism: uric acid  
 Biomarkers of bone formation or resorption: C-terminal telopeptide of Type I 
collagen ( CTX -1) and procollagen Type I N -terminal propeptide ( P1NP ) 
 Biomarkers related  to cardiovascular risk: apolipoprotein B ( ApoB ) and  
apolipoprotein C -III (Apo C3 ).  
Metabolic Mechanism  Longitudinal Biomarkers  Endpoint Biomarkers  
Insulin sensitivity  HOMA2 -IR (computed with fasting 
glucose and with fasting insulin or 
fasting C -peptide)  
IGFBP -2  
 Total adiponectin  
 
Leptin  
Pancreatic beta cell function  HOMA2 -B (computed with fasting 
glucose and with fasting insulin or 
fasting C -peptide)  
Intact proinsulin/C -peptide ratio  
Intact proinsulin/insulin ratio  
  
Fatty acid oxidation   Beta-hydroxybutyrate  
Lipolysis  Free fatty acids  
Glycerol   
Purine metabolism   Uric acid  
Approved on 29 Aug 2022 GMT
CCI
CCI
CCI
CCI
CONFIDENTIAL   J1I-MC-GZBD (c)  
 107 Metabolic Mechanism  Longitudinal Biomarkers  Endpoint Biomarkers  
Bone formation or resorption   CTX -1 
P1NP  
Cardiovascular risk   ApoB  
Apo C3  
 
 
  
Approved on 29 Aug 2022 GMT
CCI
CONFIDENTIAL   J1I-MC-GZBD (c)  
 108 10.12.  Appendix 1 2: Provisions for Changes in Study Conduct during 
Exceptional Circumstances  
Implementation of this appendix  
The changes to procedures described  in this appendix are temporary measures intended to be 
used only during specific time periods  as directed by [CONTACT_52019].  
Exceptional circumstances  
Exceptional  circumstances  are rare events  that may cause disruptions to the conduct of the study.  
Examples include  pandemics or natural disasters . These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approv al, sites may 
implement changes if permitted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bodies , and any other relevant local 
authorities, implementation of these exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required (for example, u pon implementation and suspension of  changes). All 
approvals and notifications must be retained in the study records.  
If the sponsor grants written approval for changes  in study conduct, the sponsor will also provide 
additional written guidance , if needed.  
Considerations for making a change  
The prevailing consideration  for making a change is e nsuring the safety of study participants.  
Additional i mportant considerations for making a change are compliance with GCP , enabling 
participants to continue safely in the study  and maintaining the integrity of the study.  
Informed consent  
Additional consent from the participant will be obtained, if required , for 
 participation in remote visits, as defined in Secti on “Remote Visits”  
 dispensation of additional study interv ention  during an extended treatment period  
 alternate delivery of study intervention and ancillary supplies, and 
 provision of their personal or medical information required prior to implementation of 
these activities .  
Changes in study conduct  during e xcept ional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed . 
The following changes in study conduct will not be considered protocol deviations.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 109 Remote visits       
Types  of remote visits  
Telemedicine:  
Telephone or  technology -assisted  virtual visits, or both,  are acceptable  to 
complete  appropriate  assessments.  Assessments to be completed in this manner  include, 
but are not limited to,  AEs, PCs, concomitant medications, an d review of study 
participant diary (including study drug compliance) . 
 
Mobile healthcare:   
Healthcare visits may be performed by a mobile healthcare provider at locations other 
than the study site when participants cannot travel to the site due to an exceptional 
circumstance if written approval is provided by [CONTACT_456] . Procedures performed at 
such visits include, but are not limited to,  weight and waist measurements, physical 
assessments, vital signs , PRO,  collection of blood samples , and health information.  
 
Other alternative locations:  Laboratory draws and ECGs  may be done  at an alternate 
location in exceptional circumstances.  
Data capture  
In source document s and the CRF , the study site should capture the visit method , with a specific 
explanation for any data missing because of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol r equirements regarding the 
reporting of AEs, SAEs, and PCs remain unchanged .  
Retu rn to on -site visits  
Every effort should be made to enable  participant s to return to on -site visits as soon as 
reasonably possible, while ensuring the safety of both the participant s and the site staff.  
Local laboratory testing option  
Local laboratory testing may be conducted in lieu of central laboratory testing . The local 
laboratory must be qualified in accordance with  applicable  local regulations . 
Study intervention and ancillary supplies (including participant diaries)  
When a  participant  is unable to go to the site to receive study  supplies during normal on -site 
visits, the site should work with the sponsor to determine appropriate actions . These actions may  
includ e  
 asking the  participant to go to the site and receive study  supplies from site staff 
without completion of a full study visit 
 asking the participant ’s designee to go to the site and receive study  supplies on a 
participant’s behalf, and 
 arranging delivery of study supplies . 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790900] be met  before action is taken : 
 Alternate delivery of study intervention should be performed in a manner that does 
not compromise treatment blinding and ensures product integrity. The existing 
protocol requirements for product accountability remain unchanged , including 
verification of pa rticipant’s receipt of study supplies.  
 When delivering supplies to a location other than the study site (for example, 
participant’s home ), the investigator , sponsor , or both  should ensure oversight of the 
shippi[INVESTIGATOR_597973] ( that is , storage 
conditions maintained  and intact packaging upon receipt) . 
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed  study supplies . 
Screening period  guidance   
To ensure safety of study participants, lab oratory  values and other eligibility assessments tak en 
at screening visit are valid for a maximum of [ADDRESS_790901] be paused due to 
exceptional circumstances:  
 If paused for less than 30 days from screening: the participant will proceed to the next 
study visit per the usual SoA, provided that randomization visit must be conducted 
within [ADDRESS_790902] the next visit if the participant’s eligibility criteria are 
confirmed, and the site should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm the impacted 
partici pant’s consent and document this confirmation in the source 
documentation.  
 If screening is  paused for more than 30 days from screening: the participant must be 
discontinued because of screening interruption due to an exceptional circumstance. 
This is docum ented as a screen fail in the CRF . The participant can reconsent and be 
rescreened as a new participant  as described in the protocol . This rescreen is in 
addition to the one allowed by [CONTACT_141730].  The screening procedures per the 
usual SoA should be  followed, starting at screening visit to ensure participant 
eligibility by [CONTACT_170283].  
Adjustments to visit windows  
Whenever possible and safe to do so, as determined by  [CONTACT_093]’s discretion , participants 
should complete the usual SoA. To maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance from th e sponsor . 
This minimizes missing data and preserv es the intended conduct of the stud y. 
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790903] will be documented  
 Sites will identify and document the details of how participants, visits types, and 
conducted activities were affected by [CONTACT_52022] . Dispensing  or 
shipment records of study intervention  and relevant communications, including 
delegation, should be filed with site s tudy records.  
Source documents at alternate locations  
 Source documents generated at a location other than the study site should be part of the 
investigator’s source documentation and should be transferred to the site in a secure and 
timely manner.  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 112 10.13.  Append ix 13: Abbreviations  
Term  Definition  
AC assessment committee  
ADA  anti-drug antibodies  
AE adverse event: any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a  causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whe ther or 
not related to the medicinal (investigational) product.  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
BG blood glucose  
blinding/masking  A double -blind study in which neither the participant nor any of the  investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.  
BMI  body mass index  
BP blood pressure  
CEC  clinical endpoint committee  
CHF  congestive heart failure  
CKD -EPI [INVESTIGATOR_82351] -Epi[INVESTIGATOR_597974]  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF  case report form  
CRP  clinical research physician: Individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician , or other medical officer.  
CSR  clinical study report  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 [ADDRESS_790904]  
GPS  Global Patient Safety  
HbA1c  hemoglobin A1c  
HDL  high-density lipoprotein  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 114 hERG  human ether -a-go-go-related gene  
HR heart rate  
IB Investigator’s Brochure  
ICF informed consent form  
ICH  International Council for Harmonization  
IEC Independent Ethics Committees  
Informed consent  A process by [CONTACT_9444] a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by [CONTACT_3553] a written, s igned , and dated informed consent form.  
INR international normalized ratio  
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created  or locked.  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different fro m the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
IRB Institutional Review Boards  
ISR injection site reaction  
IWRS  interactive web -response system  
LDL  low-density lipoprotein  
MAD  multiple ascending dose  
MedDRA  Medical Dictionary for Regulatory Activities  
MEN  multiple endocrine neoplasia  
MEN2  multiple endocrine neoplasia syndrome type 2  
MMRM  mixed -model for repeated measures  
MRI  magnetic  resonance imaging  
MTC  medullary thyroid carcinoma  
NAFLD  nonalcoholic fatty liver disease  
NYHA  [LOCATION_001] Heart Association  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 115 OTC  over-the-counter  
participant  Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PK/PD  pharmacokinetics/pharmacodynamics  
PR pulse rate  
PRO  patient -reported outcomes/  
QW once weekly  
SAD  single -ascending dose  
SAE  serious adverse event  
SAP  statistical analysis plan  
SC subcutaneous  
SD standard deviation  
SDP  single -dose pen  
screen  The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
SF-36 v2 Short Form -36 Health Survey (SF -36), version 2  
SMBG  self-monitoring of blood glucose  
T1DM  type 1 diabetes mellitus  
T2DM  type 2 diabetes mellitus  
TBL  total bilirubin level  
TE treatment emergent  
TEAE  Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.  
Tx treatment  
ULN  upper limit of normal  
VAS  visual analog scale  
VLDL  very low -density lipoprotein  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 116 WOCBP  women of childbearing potential  
WNOCBP  women not of childbearing potential  
  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 117 10.14.  Appendix 14: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Amendment b: 10-May -2021  
Overall Rationale for the Amendment:  
The overall changes and rationale for the changes made to this protocol are described in the 
following table. Note t hat minor edits have been made throughout the protocol, which are not 
captured in the amendment summary of changes table  below . 
Section # and Name  [CONTACT_9353] 1.3 Schedule of 
Events  Addition of the following note 
to  Patient -Reported Outcomes 
(PROs) , “If a translation is not 
available in the native language 
of a participant at baseline, the 
PRO questionnaire(s) will not 
be administered for that 
participant for the duration of 
the trial (Appendix 10.10)”  To have transl ation of PRO 
questionnaire(s) available in 
native language for participants  
 
 
Section 4.1.1  
Overview of Study 
Periods  Addition of “when collected” 
for PROs at Visit 3 and during 
maintenance period (Visits 9 -
13) To be aligned with PROs in 
Schedule of Events  
Section 8.3.1 Timing and 
Mechanism for 
Collecting Events  Change of Pregnancy eCRF to 
SAE eCRF  Editorial consistency  
Section 10.10 Appendix 
10 Patient -Reported 
Outcomes  Added information on 
translation of PRO 
questionnaire(s) not being 
available in the native language 
of a participant at baseline  To have translation of PRO 
questionnaire(s) available in 
native language for participants  
 
Section 10.2 Appendix 2: 
Clinical Laboratory Tests  Removed uric acid from 
clinical chemistry.  To maintain interna l document 
consistency. It is presented in 
Appendix 11 as biomarker of 
purine metabolism  
Added P800 to exploratory 
samples  Addition of plasma metabolic 
marker  
Section 10.9 Appendix 9: 
Protocol GZBD 
Standardized Protocols 
for the Measurement of Updated electrocardiogram 
tracings to be collected at 
baseline, 24 and 36 weeks and To maintain consistency  with 
Section 8.2.3 
(Electrocardiograms)  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 118 Section # and Name  [CONTACT_598020], Weight, Waist 
Circumference, Vital 
Signs, ECG, SMBG and 
MNSI   will be assessed qualitatively 
by a blinded cardiologist  
 
Amendment  a: March 1, 2021  
Overall Rationale for the Amendment:  
The overall changes and rationale for the changes made to this protocol are described in the 
following table. Note that minor edits have been made throughout the protocol, which are not 
captured in the amendment summary table . 
Section # and 
Name  [CONTACT_9353] 1.3 
Schedule of 
Events  Diary dispensation and return has 
been updated. An eGRF 
procedure was added at Visit 8 
(Week 12) and removed at Visit 
12 (Week 30).  The Schedule of Activities was updated 
to match operational changes related to 
diaries and to align eGFR visits with 
clinical chemistry visits.  
Section 5.1 
Inclus ion 
Criteria  The sentence “ Female 
participants should not be 
breastfeeding”   was added to 
Inclusion criteria 7.  Text added for clarification  
Section 8.3.[ADDRESS_790905]  The section heading was changed 
from “ Safety Topi[INVESTIGATOR_597975]” to “ Adverse Events  of 
Special Interest”.  “Safety topi[INVESTIGATOR_1102]” 
was changed to “adverse events” 
throughout the section.  Corrected heading to match template.  
Section wording was corrected to match 
the heading.  
Section 10.4  
Contraceptive 
Guidance -
Female 
participants 
who become 
pregnant   The greater than sign was 
changed to greater than or equal 
to in the following sentence: “ A 
spontaneous abortion (occurring 
at <20 weeks gestational age) or 
still birth (occurring at ≥20 weeks 
gestational age) is always 
considered to be an SAE and will 
be reported as such. ” Corrected error  
 
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 119 11. References  
[ADA] American Diabetes Association. 6. Glycemic targets: standards of medical care in 
diabetes -2020. Diabetes Care . 2020 ;43(suppl 1):S66 -S76. https://doi.org/10.2337/dc20 -S006  
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its 
complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a 
WHO consultatio n. Diabet Med . 1998; 15(7):539-553. https://doi.org/ 10.1002/(SICI)1096 -
9136(199807)15:7<539 :AID-DIA668>3.0.CO;2 -S 
Aroda VR, Ratner R. The safety and tolerability of GLP -1 receptor agonists in the treatment of 
type 2 diabetes: a review. Diabetes Metab Res Rev . 2011;27(6):528 -542. 
https://doi.org/10.1002/dmrr.1202  
Aroda VR. A review of GLP -1 receptor agonists: evolution and advancement, through the lens of 
randomised controlled trials. Diabetes Obes Metab.  2018;20(suppl 1):22 -33. 
https://doi.org/ 10.1111/dom.[ZIP_CODE]  
Banks PA, Freeman ML; Practice Parameters Committee of the American College of 
Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol.  
2006;101(10):2379 -2400. https://doi.org/10.1111/j.1572 -0241.2006.[ZIP_CODE].x  
Barazzoni R, Gortan Cap pellari G, Ragni M, et al. Insulin resistance in obesity: an overview of 
fundamental alterations. Eat Weight Disord.  2018;23(2):149 -157. 
https://doi.org/ 10.1007/s40519 -018-0481 -6 
Chun JH, Butts A. Long -acting GLP -1RAs: an overview of efficacy, safety, and their role in type 
2 diabetes management. JAAPA . 2020;33(8):3 -18. 
https://doi.org/ 10.1097/01.JAA.[PHONE_12399].[ZIP_CODE].bd  
Dwivedi AK, Dubey P, Cistola DP,  et al.  Association between obesity and cardiovascular 
outcomes: updated evidence from meta-analysis studie s. Curr Cardiol Rep.  2020;22(4):25. 
https://doi.org/10.1007/s11886 -020-1273 -y  
Feldman EL, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci. 
1994;21(4):S3 -7. https:// doi.org/10.1017/s0317167100040671.  
Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analog 
scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab 
Disord . 2000;24(1):38 -48. https://doi.org/ 10.1038/sj.ijo.0801083  
Garber AJ. Obesity and type 2 diabetes: which patients are at risk? Diabetes Obes Metab.  
2012;14(5):399 -408. https://doi.org/10.1111/j.1463 -1326.2011.[ZIP_CODE].x  
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 
2 diab etes. Nature . 2006;444(7121):840 -846. https://doi.org/ 10.1038/nature05482  
Lau DC, Teoh H. Impact of current and emerging glucose -lowering drugs on body weight in 
type 2 diabetes. Can J Diabetes . 2015;39(suppl 5):S148 -154. 
https:// doi.org/10.1016/j.jcjd.201 5.09.090  
Marrero DG. The prevention of type 2 diabetes: an overview. J Diabetes Sci Technol . 
2009;3(4):756 -760. https://doi.org/ 10.1177/193229680900300423  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c)  
 120 Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL; 
DCCT/EDIC Research Group.  Neuropathy among the diabetes control and complications trial 
cohort 8 years after trial completion.  Diabetes Care. 2006;29(2):340 -4. 
https:// doi.org/10.2337/diacare.29.02.06.dc05 -1549  
Maruish ME, ed. User’s Manual for the SF -36v2 Health Su rvey. 3rd ed. Lincoln, RI: Quality 
Metric Incorporated; 2011.  
Nauck MA, Meier JJ, Schmidt WE. Incretin -based glucose -lowering medications and the risk of 
acute pancreatitis and/or pancreatic cancer: reassuring data from cardio -vascular outcome trials. 
Diabetes Obes Metab . 2017;19(9):1327 -1328. https://doi.org/10.1111/dom.[ZIP_CODE]  
Neeland IJ, Ross R, Després JP, et al; International Atherosclerosis Society; International Chair 
on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ecto pic fat, 
atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol . 
2019;7(9):715 -725. https://doi.org/ 10.1016/S2213 -8587(19)[ZIP_CODE] -1 
Pereira MJ, Eriksson JW. Emerging role of SGLT -2 inhibitors for the treatment of obesity. 
Drugs. 2019;79(3):219 -230. https://doi.org/ 10.1007/s40265 -019-1057 -0 
Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common 
pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol . 2014;2(11):911 -922. 
https://doi.org/ 10.1016/S2213 -8587(14)[ZIP_CODE] -X 
Steinberg WM, Buse JB, Ghorbani MLM, et al .; LEADER Steering Committee; LEADER Trial 
Investigators. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with 
liraglutide: results from the LEADER rando mized trial. Diabetes Care.  2017a;40(7):966 -972. 
https://doi.org/10.2337/dc16 -[ADDRESS_790906] of liraglutide on amylase, lipase, and 
acute pancreatitis in participants with overweight/obesity and normoglycemia, pre diabetes, or 
type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development 
program. Diabetes Care.  2017b;40(7):839 -848. https://doi.org/10.2337/dc16 -[ADDRESS_790907] AJ and Messick S. The three -factor eating questionnaire to measure dietary restraint, 
disinhibition and hunger. J Psychosomatic Res  1985;29(1) :71-83. https://doi.org/10.1016/0022 -
3999(85)[ZIP_CODE] -8 
Trulicity  [summary of product characteristics].  Indianapolis, IN: Eli Lilly and Company ; 2020 . 
Trulicity  [package insert] . Indianapolis, IN: Eli Lilly and Company ; 2020 . 
van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once -daily GLP -1 
analog liraglutide on gastric emptying, glycem ic parameters, appetite and energy metabolism in 
obese, non -diabetic adults. Int J Obes  (Lond) . 2014;38(6):784 -793. 
https://doi.org/ 10.1038/ijo.2013.162  
Verma S, Hussain ME. Obesity and diabetes: an update. Diabetes Metab Syndr.  2017;11(1):73 -
79. https://doi.org/ 10.1016/j.dsx.2016.06.017  
[WHO] World Health Organization. WHO STEPS surveillance manual: the WHO STEPwise 
approach to noncommunicable disease risk factor surveillance.  Updated January 26, 2017. 
Accessed May 04, 2020. https://www.who.int/nc ds/surveillance/steps/STEPS_Manual.pdf  
Approved on 29 Aug 2022 GMT
CONFIDENTIAL   J1I-MC-GZBD (c) 
121 Zheng  Y, Ley SH, Hu FB . Global aetiology and epi[INVESTIGATOR_402521] 2 diabetes mellitus and its 
complications. Nat Rev Endocrinol.  2018;14(2):88 -98. https://doi.org/ 10.1038/nrendo.2017.151  
Approved on 29 Aug 2022 GMT
Signature [CONTACT_11032]-CLIN-072318 v1.0
Signature [CONTACT_11032]-CLIN-072318 v1.0Approval
tor
25-Aug-2022 22:03:40 GMT[PHONE_006]
Approval
anagement
29-Aug-2022 15:14:27 GMT[PHONE_006]Approved on 29 Aug 2022 GMT
[COMPANY_003]
[COMPANY_003]